# EDGAR Filing Document

**Accession Number:** 0001794783
**File Stem:** 0001794783-23-000014
**Filing Date:** 2023-2
**Character Count:** 219649
**Document Hash:** 64a5c4c7adc12964cc05fe00aa2f693c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001794783-23-000014.hdr.sgml**: 20230207

**ACCESSION NUMBER**: 0001794783-23-000014

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 86

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SelectQuote, Inc.
- **CENTRAL INDEX KEY:** 0001794783
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **IRS NUMBER:** 943339273
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39295
- **FILM NUMBER:** 23592785

**BUSINESS ADDRESS:**
- **STREET 1:** 6800 WEST 115TH STREET
- **STREET 2:** SUITE 2511
- **CITY:** OVERLAND PARK
- **STATE:** KS
- **ZIP:** 66211
- **BUSINESS PHONE:** 9132741994

**MAIL ADDRESS:**
- **STREET 1:** 6800 WEST 115TH STREET
- **STREET 2:** SUITE 2511
- **CITY:** OVERLAND PARK
- **STATE:** KS
- **ZIP:** 66211

?xml version="1.0" ? slqt-20221231

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2022**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**001-39295**

(Commission File Number)

**SelectQuote, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **Delaware** | **94-3339273** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **6800 West 115th Street** | **Suite 2511** | **66211** |
| **Overland Park** | **Kansas** | (Zip Code) |
| (Address of principal executive offices) | (Address of principal executive offices) | |

---

**(913) 599-9225**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | SLQT | New York Stock Exchange |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &nbsp;&nbsp;&nbsp;&nbsp;Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ☐ No ☒

The registrant had outstanding 166,511,722 shares of common stock as of January 31, 2023.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | **PART I FINANCIAL INFORMATION** | **PAGE** |
| &nbsp;&nbsp;&nbsp;<u>Item 1.</u> | <u>[Financial Statements (unaudited)](#icb71b0e22bc6448b866d18eb9d59d019_10)</u> |  |
|  | <u>[Condensed Consolidated Balance Sheets as of](#icb71b0e22bc6448b866d18eb9d59d019_16)[December](#icb71b0e22bc6448b866d18eb9d59d019_16)[31](#icb71b0e22bc6448b866d18eb9d59d019_16)[, 2022 and June 30, 202](#icb71b0e22bc6448b866d18eb9d59d019_16)[2](#icb71b0e22bc6448b866d18eb9d59d019_16)</u> | <u>[2](#icb71b0e22bc6448b866d18eb9d59d019_16)</u> |
|  | <u>[Condensed Consolidated Statements of Comprehensive](#icb71b0e22bc6448b866d18eb9d59d019_19)[Income (](#icb71b0e22bc6448b866d18eb9d59d019_19)[Loss](#icb71b0e22bc6448b866d18eb9d59d019_19)[)](#icb71b0e22bc6448b866d18eb9d59d019_19)[for the Three](#icb71b0e22bc6448b866d18eb9d59d019_19)[and Six](#icb71b0e22bc6448b866d18eb9d59d019_19)[Months Ended](#icb71b0e22bc6448b866d18eb9d59d019_19)[D](#icb71b0e22bc6448b866d18eb9d59d019_19)[ecember](#icb71b0e22bc6448b866d18eb9d59d019_19)[31](#icb71b0e22bc6448b866d18eb9d59d019_19)[, 2022](#icb71b0e22bc6448b866d18eb9d59d019_19)[and 2021](#icb71b0e22bc6448b866d18eb9d59d019_19)</u> | <u>[3](#icb71b0e22bc6448b866d18eb9d59d019_19)</u> |
|  | <u>[Condensed Consolidated Statements of Changes in Shareholders' Equity for the](#icb71b0e22bc6448b866d18eb9d59d019_22)[Three and Six Months Ended December 31, 2022 and 2021](#icb71b0e22bc6448b866d18eb9d59d019_22)</u> | <u>[4](#icb71b0e22bc6448b866d18eb9d59d019_22)</u> |
|  | <u>[Condensed Consolidated Statements of Cash Flows for the](#icb71b0e22bc6448b866d18eb9d59d019_28)[Six](#icb71b0e22bc6448b866d18eb9d59d019_28)[Months Ended](#icb71b0e22bc6448b866d18eb9d59d019_28)[D](#icb71b0e22bc6448b866d18eb9d59d019_28)[ecember](#icb71b0e22bc6448b866d18eb9d59d019_28)[3](#icb71b0e22bc6448b866d18eb9d59d019_28)[1](#icb71b0e22bc6448b866d18eb9d59d019_28)[, 2022](#icb71b0e22bc6448b866d18eb9d59d019_28)[and 2021](#icb71b0e22bc6448b866d18eb9d59d019_28)</u> | <u>[6](#icb71b0e22bc6448b866d18eb9d59d019_28)</u> |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#icb71b0e22bc6448b866d18eb9d59d019_31)</u> | <u>[7](#icb71b0e22bc6448b866d18eb9d59d019_31)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 2.</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#icb71b0e22bc6448b866d18eb9d59d019_76)</u> | <u>[32](#icb71b0e22bc6448b866d18eb9d59d019_76)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 3.</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#icb71b0e22bc6448b866d18eb9d59d019_106)</u> | <u>[56](#icb71b0e22bc6448b866d18eb9d59d019_106)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 4.</u> | <u>[Controls and Procedures](#icb71b0e22bc6448b866d18eb9d59d019_109)</u> | <u>[56](#icb71b0e22bc6448b866d18eb9d59d019_109)</u> |
|  | **PART II OTHER INFORMATION** |  |
| &nbsp;&nbsp;&nbsp;<u>Item 1.</u> | <u>[Legal Proceedings](#icb71b0e22bc6448b866d18eb9d59d019_115)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_115)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 1A.</u> | <u>[Risk Factors](#icb71b0e22bc6448b866d18eb9d59d019_118)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_118)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 2.</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#icb71b0e22bc6448b866d18eb9d59d019_121)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_121)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 3.</u> | <u>[Defaults Upon Senior Securities](#icb71b0e22bc6448b866d18eb9d59d019_124)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_124)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 4.</u> | <u>[Mine Safety Disclosures](#icb71b0e22bc6448b866d18eb9d59d019_127)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_127)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 5.</u> | <u>[Other Information](#icb71b0e22bc6448b866d18eb9d59d019_130)</u> | <u>[58](#icb71b0e22bc6448b866d18eb9d59d019_130)</u> |
| &nbsp;&nbsp;&nbsp;<u>Item 6.</u> | <u>[Exhibits](#icb71b0e22bc6448b866d18eb9d59d019_133)</u> | <u>[59](#icb71b0e22bc6448b866d18eb9d59d019_133)</u> |
|  | <u>[Signatures](#icb71b0e22bc6448b866d18eb9d59d019_136)</u> | <u>[60](#icb71b0e22bc6448b866d18eb9d59d019_136)</u> |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**PART I**

**FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2022** | **June 30, 2022** |
| ASSETS |  |  |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $36097 | $140997 |
| &nbsp;&nbsp;Accounts receivable, net of allowances of $1.8 million and $0.6 million, respectively | 134912 | 129748 |
| &nbsp;&nbsp;Commissions receivable-current | 219990 | 116277 |
| &nbsp;&nbsp;Other current assets | 13384 | 15751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 404383 | 402773 |
| COMMISSIONS RECEIVABLE—Net | 733337 | 722349 |
| PROPERTY AND EQUIPMENT—Net | 34786 | 41804 |
| SOFTWARE—Net | 16099 | 16301 |
| OPERATING LEASE RIGHT-OF-USE ASSETS | 27285 | 28016 |
| INTANGIBLE ASSETS—Net | 28411 | 31255 |
| GOODWILL | 29136 | 29136 |
| OTHER ASSETS | 24476 | 18418 |
| TOTAL ASSETS | $1297913 | $1290052 |
| LIABILITIES AND SHAREHOLDERS' EQUITY |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;Accounts payable | $27356 | $24766 |
| &nbsp;&nbsp;Accrued expenses | 21859 | 26002 |
| &nbsp;&nbsp;Accrued compensation and benefits | 46065 | 42150 |
| &nbsp;&nbsp;Operating lease liabilities—current | 6349 | 5261 |
| &nbsp;&nbsp;Current portion of long-term debt | 21400 | 7169 |
| &nbsp;&nbsp;Contract liabilities | 38752 | 3404 |
| &nbsp;&nbsp;Other current liabilities | 2374 | 4761 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 164155 | 113513 |
| LONG-TERM DEBT, NET—less current portion | 670119 | 698423 |
| DEFERRED INCOME TAXES | 46896 | 50080 |
| OPERATING LEASE LIABILITIES | 31749 | 33946 |
| OTHER LIABILITIES | 3229 | 2985 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 916148 | 898947 |
| COMMITMENTS AND CONTINGENCIES (Note 8) |  |  |
| SHAREHOLDERS' EQUITY: |  |  |
| &nbsp;&nbsp;Common stock, $0.01 par value | 1665 | 1644 |
| &nbsp;&nbsp;Additional paid-in capital | 561435 | 554845 |
| &nbsp;&nbsp;Accumulated deficit | (197070) | (177100) |
| &nbsp;&nbsp;Accumulated other comprehensive income | 15735 | 11716 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 381765 | 391105 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $1297913 | $1290052 |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(Unaudited)**

**(In thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| REVENUE: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission | $230033 | $139957 | $336368 | $270764 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharmacy | 51601 | 8770 | 92694 | 13237 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 37554 | 45510 | 52610 | 66315 |
| Total revenue | 319188 | 194237 | 481672 | 350316 |
| OPERATING COSTS AND EXPENSES: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of revenue | 91477 | 136189 | 156641 | 222980 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold—pharmacy revenue | 50096 | 10172 | 92450 | 15043 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketing and advertising | 89925 | 193246 | 147519 | 283923 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 28412 | 21894 | 59118 | 45789 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technical development | 6245 | 6386 | 12427 | 12239 |
| Total operating costs and expenses | 266155 | 367887 | 468155 | 579974 |
| INCOME (LOSS) FROM OPERATIONS | 53033 | (173650) | 13517 | (229658) |
| INTEREST EXPENSE, NET | (21044) | (10587) | (37780) | (19122) |
| OTHER INCOME (EXPENSE), NET | (70) | (51) | 88 | (153) |
| INCOME (LOSS) BEFORE INCOME TAX EXPENSE (BENEFIT) | 31919 | (184288) | (24175) | (248933) |
| INCOME TAX EXPENSE (BENEFIT) | 9405 | (46725) | (4205) | (63138) |
| NET INCOME (LOSS) | $22514 | $(137563) | $(19970) | $(185795) |
| NET INCOME (LOSS) PER SHARE: |  |  |  |  |
| &nbsp;&nbsp;Basic | $0.14 | $(0.84) | $(0.12) | $(1.13) |
| &nbsp;&nbsp;Diluted | $0.14 | $(0.84) | $(0.12) | $(1.13) |
| WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: |  |  |  |  |
| &nbsp;&nbsp;Basic | 166486 | 163966 | 165655 | 163829 |
| &nbsp;&nbsp;Diluted | 166548 | 163966 | 165655 | 163829 |
| OTHER COMPREHENSIVE INCOME (LOSS) NET OF TAX: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (loss) on cash flow hedge | (381) | 1775 | 4019 | 1769 |
| OTHER COMPREHENSIVE INCOME (LOSS) | (381) | 1775 | 4019 | 1769 |
| COMPREHENSIVE INCOME (LOSS) | $22133 | $(135788) | $(15951) | $(184026) |

---

See accompanying notes to the condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY** 

**(Unaudited)**

**(In thousands)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| **BALANCES-September 30, 2022** | 166462 | $1665 | $558501 | $(219584) | $16116 | $356698 |
| &nbsp;&nbsp;Net income |  |  |  | 22514 |  | 22514 |
| &nbsp;&nbsp;Gain on cash flow hedge, net of tax |  |  |  |  | 1255 | 1255 |
| &nbsp;&nbsp;Amount reclassified into earnings, net tax |  |  |  |  | (1636) | (1636) |
| &nbsp;&nbsp;Exercise of employee stock options, net of shares withheld for cashless exercises and to cover tax withholdings |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of common stock pursuant to employee stock purchase plan |  |  |  |  |  |  |
| &nbsp;&nbsp;Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings | 49 |  | (2) |  |  | (2) |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 2936 |  |  | 2936 |
| **BALANCES-December 31, 2022** | 166511 | $1665 | $561435 | $(197070) | $15735 | $381765 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Retained Earnings/(Accumulated Deficit)** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Retained Earnings/(Accumulated Deficit)** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| **BALANCES-September 30, 2021** | 163930 | $1639 | $549034 | $72172 | $223 | $623068 |
| &nbsp;&nbsp;Net loss |  |  |  | (137563) |  | (137563) |
| &nbsp;&nbsp;Gain on cash flow hedge, net of tax |  |  |  |  | 1602 | 1602 |
| &nbsp;&nbsp;Amount reclassified into earnings, net of tax |  |  |  |  | 173 | 173 |
| &nbsp;&nbsp;Exercise of employee stock options, net of shares withheld for cashless exercises and to cover tax withholdings | 55 |  | 76 |  |  | 76 |
| &nbsp;&nbsp;Issuance of common stock pursuant to employee stock purchase plan |  |  |  |  |  |  |
| &nbsp;&nbsp;Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings | 28 | 1 | (2) |  |  | (1) |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 1894 |  |  | 1894 |
| **BALANCES-December 31, 2021** | 164013 | $1640 | $551002 | $(65391) | $1998 | $489249 |

---

See accompanying notes to the condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** | **Six Months Ended December 31, 2022** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated Deficit** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| **BALANCES-June 30, 2022** | 164452 | $1644 | $554845 | $(177100) | $11716 | $391105 |
| &nbsp;&nbsp;Net loss |  |  |  | (19970) |  | (19970) |
| &nbsp;&nbsp;Gain on cash flow hedge, net of tax |  |  |  |  | 6379 | 6379 |
| &nbsp;&nbsp;Amount reclassified into earnings, net of tax |  |  |  |  | (2360) | (2360) |
| &nbsp;&nbsp;Exercise of employee stock options, net of shares withheld for cashless exercises and to cover tax withholdings | 1116 | 12 | 584 |  |  | 596 |
| &nbsp;&nbsp;Issuance of common stock pursuant to employee stock purchase plan | 781 | 8 | 476 |  |  | 484 |
| &nbsp;&nbsp;Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings | 162 | 1 | (36) |  |  | (35) |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 5566 |  |  | 5566 |
| **BALANCES-December 31, 2022** | 166511 | $1665 | $561435 | $(197070) | $15735 | $381765 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Retained Earnings/(Accumulated Deficit)** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Retained Earnings/(Accumulated Deficit)** | **Accumulated Other Comprehensive Income** | **Total<br>Shareholders'<br>Equity** |
| **BALANCES-June 30, 2021** | 163510 | $1635 | $544771 | $120404 | $229 | $667039 |
| &nbsp;&nbsp;Net loss |  |  |  | (185795) |  | (185795) |
| &nbsp;&nbsp;Gain on cash flow hedge, net of tax |  |  |  |  | 1423 | 1423 |
| &nbsp;&nbsp;Amount reclassified into earnings, net tax |  |  |  |  | 346 | 346 |
| &nbsp;&nbsp;Exercise of employee stock options, net of shares withheld for cashless exercises and to cover tax withholdings | 339 | 3 | 1279 |  |  | 1282 |
| &nbsp;&nbsp;Issuance of common stock pursuant to employee stock purchase plan | 90 | 1 | 988 |  |  | 989 |
| &nbsp;&nbsp;Vesting of restricted stock unit awards net of shares withheld to cover tax withholdings | 74 | 1 | (145) |  |  | (144) |
| &nbsp;&nbsp;Share-based compensation expense |  |  | 4109 |  |  | 4109 |
| **BALANCES-December 31, 2021** | 164013 | $1640 | $551002 | $(65391) | $1998 | $489249 |

---

See accompanying notes to the condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(In thousands**)

---

| | | |
|:---|:---|:---|
| | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Net loss | $(19970) | $(185795) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 13990 | 11278 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property, equipment, and software | 376 | 355 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 5566 | 4109 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (4572) | (63498) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and debt discount | 3919 | 2974 |
| &nbsp;&nbsp;&nbsp;&nbsp;Write-off of debt issuance costs | 710 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest payable in kind | 4920 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease expense | 2082 | 2040 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 14036 | (41237) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commissions receivable | (114701) | (39908) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 1578 | (5555) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 950 | 15135 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (2460) | (2676) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 18002 | (2963) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (75574) | (305741) |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Purchases of property and equipment | (598) | (17904) |
| &nbsp;&nbsp;Purchases of software and capitalized software development costs | (3870) | (5231) |
| &nbsp;&nbsp;Acquisition of business |  | (6927) |
| &nbsp;&nbsp;Investment in equity securities |  | (1000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (4468) | (31062) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;Proceeds from Revolving Credit Facility |  | 50000 |
| &nbsp;&nbsp;Payments on Revolving Credit Facility |  | (50000) |
| &nbsp;&nbsp;Proceeds from Term Loans |  | 242000 |
| &nbsp;&nbsp;Payments on Term Loans | (13375) |  |
| &nbsp;&nbsp;Payments on other debt | (83) | (93) |
| &nbsp;&nbsp;Proceeds from common stock options exercised and employee stock purchase plan | 1078 | 2271 |
| &nbsp;&nbsp;Payments of tax withholdings related to net share settlement of equity awards | (33) | (144) |
| &nbsp;&nbsp;Payments of debt issuance costs | (10110) | (328) |
| &nbsp;&nbsp;Payment of acquisition holdback | (2335) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by financing activities | (24858) | 243706 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (104900) | (93097) |
| CASH AND CASH EQUIVALENTS—Beginning of period | 140997 | 286454 |
| CASH AND CASH EQUIVALENTS—End of period | $36097 | $193357 |

---

---

| | | |
|:---|:---|:---|
| SUPPLEMENTAL CASH FLOW INFORMATION: |  |  |
| &nbsp;&nbsp;Interest paid, net | $(27872) | $(15447) |
| &nbsp;&nbsp;Income taxes paid, net | (12) | (19) |

---

See accompanying notes to condensed consolidated financial statements.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SELECTQUOTE, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**1. SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES**

**Description of Business**—SelectQuote, Inc. (together with its subsidiaries, the "Company" or "SelectQuote") is a leading technology-enabled, direct-to-consumer distribution platform for insurance products and healthcare services. We contract with insurance carriers to sell senior health, life, and auto and home insurance policies by telephone to individuals throughout the United States through the use of multi-channel marketing and advertising campaigns. SelectQuote's Senior division ("Senior") sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote's Life division ("Life") sells term life, final expense, and other ancillary products, and SelectQuote's Auto & Home division ("Auto & Home") primarily sells non-commercial auto and home, property and casualty insurance products. The Healthcare Services division ("Healthcare Services") includes SelectRx and Population Health. SelectRx is a closed-door, long-term care pharmacy, which offers essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services. Population Health contracts with insurance carriers to perform health risk assessments ("HRA") on potential new members to determine how Population Health's value-based care ("VBC") partners can help members improve health outcomes.

**Basis of Presentation**—The accompanying unaudited condensed consolidated financial statements include the accounts of SelectQuote, Inc. and its wholly owned subsidiaries: SelectQuote Insurance Services, SelectQuote Auto & Home Insurance Services, LLC ("SQAH"), ChoiceMark Insurance Services, Inc., Tiburon Insurance Services, InsideResponse, LLC ("InsideResponse"), and SelectQuote Ventures, Inc. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended June 30, 2022, filed with the Securities and Exchange Commission on August 29, 2022 (the "Annual Report"), and include all adjustments necessary for the fair presentation of our financial position for the periods presented. Our results for the periods presented in our financial statements are not necessarily indicative of the results to be expected for any subsequent period, including for the year ending June 30, 2023, and therefore should not be relied upon as an indicator of future results. The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2022. During the six months ended December 31, 2022, the Company created a new liability line item on the condensed consolidated balance sheets for "Contract liabilities" which was previously included in "Other current liabilities" in the Company's Annual Report. The Company created a new revenue line item on the condensed consolidated statements of comprehensive income for "Pharmacy revenue" which was previously included in "Other revenue" in the Company's Annual Report. Production bonus revenue, which was previously presented separately within Revenue in the Annual Report, is now included in Other revenue. Additionally, the Company created a new operating costs and expenses line item for "Cost of goods sold-pharmacy revenue" related to "Pharmacy revenue" which was previously included in "Cost of revenue" in the Company's Annual Report. The Company updated its accounting policy related to the classification of SelectRx cost of goods sold which resulted in $1.7 million and $2.3 million previously included in Cost of revenue in the condensed consolidated financial statements for the three and six months ended December 31, 2021, respectively, now included in Selling, general, and administrative expenses. Prior year financial statements and disclosures were reclassified to conform to these changes in presentation. These reclassifications had no impact on net income, shareholders' equity or cash flows as previously reported.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Use of Estimates**—The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and disclosure of contingent assets and liabilities. The Company regularly assesses these estimates; however, actual amounts could differ from those estimates. The most significant items involving management's estimates include estimates of revenue recognition, accounts receivable, net, commissions receivable, the provision for income taxes, share-based compensation, and valuation of intangible assets and goodwill. The impact of changes in estimates is recorded in the period in which they become known.

**Seasonality**—Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year during the Medicare annual enrollment period ("AEP") in October through December and are allowed to switch plans from an existing plan during the open enrollment period ("OEP") in January through March each year. As a result, the Company's Senior segment's commission revenue is highest in the second quarter and to a lesser extent, the third quarter during OEP.

**Significant Accounting Policies**—There have been no material changes to the Company's significant accounting policies as described in our 2022 Annual Report, other than the changes to the policies below as discussed above:

***Cost of Revenue***—Cost of revenue represents the direct costs associated with fulfilling the Company's obligations to its customers to sell insurance policies and other healthcare services in the Senior, Life, Auto & Home, and Population Health divisions. Such costs primarily consist of compensation, benefits, and licensing for sales agents, customer success agents, fulfillment specialists, and others directly engaged in serving customers, in addition to certain facilities overhead costs such as rent, maintenance, and depreciation.

***Cost of Goods Sold-Pharmacy Revenue***—Cost of goods sold-pharmacy revenue represents the direct costs associated with fulfilling pharmacy patient orders for SelectRx. Such costs primarily consist of medication costs and compensation and related benefit costs for licensed pharmacists, pharmacy technicians, and other employees directly associated with fulfilling orders such as packaging and shipping clerks. It also includes shipping, supplies, other order fulfillment costs including part of the one-time customer onboarding costs, and certain facilities overhead costs such as rent, maintenance, and depreciation related to the pharmacy production process.

**Recent Accounting Pronouncements Adopted**—In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers*, which requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if the acquirer had originated the contracts. Prior to this ASU, an acquirer generally recognizes contract assets acquired and contract liabilities assumed that arose from contracts with customers at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The ASU is to be applied prospectively to business combinations occurring on or after the effective date of the amendment (or if adopted early as of an interim period, as of the beginning of the fiscal year that includes the interim period of early application). The Company early adopted this guidance during the six months ended December 31, 2022, and will apply it prospectively to any business acquisitions subsequent to the date of adoption.

**Immaterial Correction of Prior Period Financial Statements**—Subsequent to the issuance of the Company's financial statements as of and for the year ended June 30, 2021, the Company determined that the provision for first year commission revenue for certain final expense policies offered by certain of its insurance carrier partners should have been accrued based on a higher lapse rate. This misstatement was initially thought to be isolated to an error in the lapse rate for one of its insurance carrier partners, as disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2021. However, during the three months ended June 30, 2022, it was determined that the lapse rate for other insurance carrier partners were also incorrect, resulting in an

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

additional misstatement being identified. The cumulative effect of the error in the lapse rates resulted in commission revenues being misstated by $7.8 million and $2.2 million for the years ended June 30, 2021 and 2020, respectively, and $3.8 million, $0.7 million, and $0.8 million for the three months ended September 30, 2021, December 31, 2021, and March 31, 2022, respectively. Accounts receivable was misstated by $10.0 million and $2.2 million as of June 30, 2021 and 2020, respectively. The impact of the cumulative misstatements on net income for the years ended June 30, 2021 and 2020, were decreases of $6.2 million and $1.7 million, respectively. Management evaluated the cumulative misstatements and concluded they were not material to prior periods, individually or in aggregate. However, correcting the cumulative effect of the misstatements during any three month period within the year ended June 30, 2022, would have had a significant effect on the results of operations for these respective reporting periods. Therefore, the Company is correcting the relevant prior period condensed consolidated financial statements and related footnotes for this error for comparative purposes.

The following tables reflect the effects of the correction on all affected line items of the Company's previously reported condensed consolidated financial statements presented in this Form 10-Q:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)** |
| | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** |
| *(in thousands)* | **As Previously Reported** | **Adjustment** | **As Corrected** | **As Previously Reported** | **Adjustment** | **As Corrected** |
| Commission revenue | $140701 | $(744) | $139957 | $272956 | $(2192) | $270764 |
| Total revenue | 194981 | (744) | 194237 | 352508 | (2192) | 350316 |
| Loss from operations | (172906) | (744) | (173650) | (227466) | (2192) | (229658) |
| Loss before income tax benefit | (183544) | (744) | (184288) | (246741) | (2192) | (248933) |
| Income tax benefit | (46536) | (189) | (46725) | (62580) | (558) | (63138) |
| Net loss | (137008) | (555) | (137563) | (184161) | (1634) | (185795) |
| Net loss per share: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | (0.84) |  | (0.84) | (1.12) | (0.01) | (1.13) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | (0.84) |  | (0.84) | (1.12) | (0.01) | (1.13) |
| Comprehensive loss | $(135233) | $(555) | $(135788) | $(182392) | $(1634) | $(184026) |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | |
|:---|:---|:---|
| **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** |
| | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
| *(in thousands)* | **(Accumulated Deficit)/Retained Earnings** | **Total<br>Shareholders'<br>Equity** |
| **As Previously Reported** |  |  |
| BALANCES-September 30, 2021 | $74772 | $625668 |
| &nbsp;&nbsp;Net loss | (137008) | (137008) |
| BALANCES-December 31, 2021 | (62236) | 492404 |
| **Adjustments** |  |  |
| BALANCES-September 30, 2021 | (2600) | (2600) |
| &nbsp;&nbsp;Net loss | (555) | (555) |
| BALANCES-December 31, 2021 | (3155) | (3155) |
| **As Corrected** |  |  |
| BALANCES-September 30, 2021 | 72172 | 623068 |
| &nbsp;&nbsp;Net loss | (137563) | (137563) |
| BALANCES-December 31, 2021 | $(65391) | $489249 |

---

---

| | | |
|:---|:---|:---|
| **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)** |
| | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** |
| *(in thousands)* | **(Accumulated Deficit)/Retained Earnings** | **Total<br>Shareholders'<br>Equity** |
| **As Previously Reported** |  |  |
| BALANCES-June 30, 2021 | $121925 | $668560 |
| &nbsp;&nbsp;Net loss | (184161) | (184161) |
| BALANCES-December 31, 2021 | (62236) | 492404 |
| **Adjustments** |  |  |
| BALANCES-June 30, 2021 | (1521) | (1521) |
| &nbsp;&nbsp;Net loss | (1634) | (1634) |
| BALANCES-December 31, 2021 | (3155) | (3155) |
| **As Corrected** |  |  |
| BALANCES-June 30, 2021 | 120404 | 667039 |
| &nbsp;&nbsp;Net Income | (185795) | (185795) |
| BALANCES-December 31, 2021 | $(65391) | $489249 |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | |
|:---|:---|:---|:---|
| **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited)** | **CORRECTED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited)** |
| | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** | **Six Months Ended December 31, 2021** |
| *(in thousands)* | **As Previously Reported** | **Adjustment** | **As Corrected** |
| Net loss | $(184161) | $(1634) | $(185795) |
| Deferred income taxes | (62940) | (558) | (63498) |
| Accounts receivable | (43429) | 2192 | (41237) |
| Net cash used in operating activities | $(305741) | $— | $(305741) |

---

**2. ACQUISITIONS**

In accordance with Accounting Standards Codification ("ASC") 805, *Business Combinations* ("ASC 805"), the Company allocates the fair value of purchase consideration to the tangible assets, liabilities, and intangible assets acquired based on fair values. Any excess purchase price over those fair values is recorded as goodwill. The fair value assigned to intangible assets acquired is supported by valuations using estimates and assumptions provided by management. Based on the valuation inputs, the Company has recorded assets acquired and liabilities assumed according to the following fair value hierarchy:

---

| | |
|:---|:---|
| Level 1 | Unadjusted quoted prices in active markets for identical assets or liabilities |
| Level 2 | Unadjusted quoted prices in active markets for similar assets or liabilities; or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. |
| Level 3 | Significant unobservable inputs for the asset or liability |

---

&nbsp;&nbsp;&nbsp;&nbsp;

**Express Med Pharmaceuticals**—On April 30, 2021, the Company acquired 100% of the outstanding shares of Express Med Pharmaceuticals, Inc., which is included in SelectRx, a closed-door, long term care pharmacy provider, for an aggregate purchase price of up to $24.0 million (subject to customary adjustments), as set forth in the Stock Purchase Agreement dated April 30, 2021 (the "Stock Purchase Agreement"). The aggregate purchase price of up to $24.0 million is comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any. The primary purpose of the acquisition was to take advantage of the Company's technology and customer base to facilitate better patient care through coordination of strategic, value-based care partnerships. The Company recorded $0.3 million of acquisition-related costs in selling, general, and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income. In addition, as a result of the acquisition, the Company has entered into an operating lease with the former President and Chief Executive Officer of Express Med Pharmaceuticals, now the Company' Executive Vice President of SelectRx. Refer to Note 6 in the condensed consolidated financial statements for further details.

The earnout of up to $4.0 million is comprised of two separate provisions. The first provision provides for an earnout of up to $3.0 million and is contingent upon achievement of the following within the first 20 months following the acquisition: facility updates that would allow for processing a minimum of 75,000 active patients, the issuance of pharmacy licenses in all 50 states, and active patients of 15,000 or more. The second provision provides for an earnout of up to $1.0 million and is contingent upon achievement of the following within 36 months following the acquisition: construction of a new facility to accommodate the servicing of additional active patients or 75,000 or more active patients as of the last day of any month prior to the end of the second earnout provision period or as of the end of the second earnout provision period. As the earnout payment is contingent upon continued employment of certain individuals, the Company will recognize the earnout as compensation expense in selling, general, and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income in the period in which it is earned. During the six months ended December 31, 2022, the Company paid the second earnout provision of $1.0 million, as well as the remaining holdback, net of adjustments, of $2.3 million. As the

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

maximum range of outcomes for the first earnout provision was achieved, the Company accrued $3.0 million as of December 31, 2022, in compensation expense in selling, general, and administrative operating costs and expenses in the condensed consolidated statement of comprehensive income, which was subsequently paid in January 2023.

Under the terms of the Stock Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands):

---

| | |
|:---|:---|
| Base purchase price | $20000 |
| Net working capital true-up | (483) |
| Closing cash | 20 |
| &nbsp;&nbsp;**Total purchase consideration** | $19537 |

---

At the date of acquisition, the fair value of net tangible assets acquired, excluding property and equipment, approximated their carrying value. The property and equipment was valued primarily using the cost and sales comparison approach to value. For the proprietary software acquired, the replacement cost method under the cost approach was used, estimating the cost to rebuild the software. The non-compete agreement was valued using the income approach, and the customer relationships were valued using the multiple period excess earnings method. As such, all aforementioned intangible assets were valued using Level 3 inputs.

Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the SelectRx business with the Company's technology and existing customer base. This acquired goodwill is allocated to the Healthcare Services reporting unit, which is also a reportable segment, and $16.3 million is deductible for tax purposes after adding back acquisition costs and excluding the holdback.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):

---

| | | |
|:---|:---|:---|
| **Description** | **Estimated Life** | **Amount** |
| Cash and cash equivalents |  | $20 |
| Accounts receivable |  | 613 |
| Other current assets |  | 28 |
| Property and equipment, net |  | 287 |
| Accounts payable |  | (280) |
| Accrued expenses, including compensation and benefits |  | (45) |
| Net tangible assets acquired |  | 623 |
| Proprietary Software | 3 years | 550 |
| Non-compete agreements | 5 years | 100 |
| Customer relationships | 1 year | 200 |
| Goodwill | Indefinite | 18064 |
| Total intangible assets acquired |  | 18914 |
| **Net assets acquired** |  | $19537 |

---

The Company will amortize the intangible assets acquired on a straight-line basis over their estimated remaining lives, ranging from one to five years.&nbsp;&nbsp;&nbsp;&nbsp;

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Simple Meds**—On August 31, 2021, SelectRx acquired 100% of the outstanding equity interests of Simple Meds, a full-service pharmaceutical distributor, for an aggregate purchase price of $7.0 million (subject to customary adjustments), as set forth in the Membership Interest Purchase Agreement dated August 31, 2021. The aggregate purchase price of $7.0 million was paid in cash at the closing of the transaction. The primary purpose of the acquisition was to accelerate the expansion of the prescription drug management business by combining the operations and existing infrastructure of Simple Meds into SelectRx.

Under the terms of the Membership Interest Purchase Agreement, total consideration in the acquisition consisted of the following as of the acquisition date (in thousands):

---

| | |
|:---|:---|
| Base purchase price | $7000 |
| Net working capital true-up | 347 |
| Closing cash | 61 |
| &nbsp;&nbsp;**Total purchase consideration** | $7408 |

---

At the date of acquisition, the fair value of net tangible assets acquired approximated their carrying value. The customer relationships were valued using the multiple period excess earnings method, and as such, were valued using Level 3 inputs.

Goodwill resulting from the transaction constitutes the excess of the consideration paid over the fair values of the assets acquired and liabilities assumed and primarily represents the additional value of the synergies of combining the Simple Meds business with the Company's technology and existing customer base. This acquired goodwill is allocated to the Healthcare Services reporting unit, which is also a reportable segment, and $5.6 million is deductible for tax purposes after adding back acquisition costs.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands):

---

| | | |
|:---|:---|:---|
| **Description** | **Estimated Life** | **Amount** |
| Cash and cash equivalents |  | $61 |
| Accounts receivable |  | 634 |
| Other current assets |  | 474 |
| Property and equipment, net |  | 415 |
| Accounts payable |  | (259) |
| Net tangible assets acquired |  | 1325 |
| Customer relationships | 1 year | 370 |
| Goodwill | Indefinite | 5713 |
| Total intangible assets acquired |  | 6083 |
| **Net assets acquired** |  | $7408 |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**3. PROPERTY AND EQUIPMENT—NET**

Property and equipment—net consisted of the following:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **December 31, 2022** | **June 30, 2022** |
| Computer hardware | $25228 | $23303 |
| Machinery and equipment<sup>(1)</sup> | 14756 | 15051 |
| Leasehold improvements | 20100 | 20269 |
| Furniture and fixtures | 4551 | 4605 |
| Work in progress | 951 | 2810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 65586 | 66038 |
| Less accumulated depreciation | (30800) | (24234) |
| **Property and equipment—net** | $34786 | $41804 |

---

(1) Includes financing lease right-of-use assets.

Work in progress as of December 31, 2022, primarily represents computer equipment not yet put into service and not yet being depreciated. Work in progress as of June 30, 2022, primarily represents computer equipment and machinery not yet put into service and not yet being depreciated. Depreciation expense for the three months ended December 31, 2022 and 2021, was $3.7 million and $2.9 million, respectively, and $7.2 million and $5.1 million for the six months ended December 31, 2022 and 2021, respectively.

**4. SOFTWARE—NET**

Software—net consisted of the following:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **December 31, 2022** | **June 30, 2022** |
| Software | $32880 | $26049 |
| Work in progress | 856 | 4162 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 33736 | 30211 |
| Less accumulated amortization | (17637) | (13910) |
| **Software—net** | $16099 | $16301 |

---

Work in progress as of December 31, 2022 and June 30, 2022, represents costs incurred for software not yet put into service and not yet being amortized. For the three months ended December 31, 2022 and 2021, the Company capitalized internal-use software and website development costs of $1.8 million and $2.0 million, respectively, and recorded amortization expense of $2.1 million and $1.5 million, respectively. For the six months ended December 31, 2022 and 2021, the Company capitalized internal-use software and website development costs of $3.9 million and $4.5 million, respectively, and recorded amortization expense of $3.9 million and $2.9 million, respectively.

**5. INTANGIBLE ASSETS AND GOODWILL**

***Intangible assets*—**The carrying amounts, accumulated amortization, and net carrying value of our definite-lived intangible assets are presented in the table below (dollars in thousands):

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** |
| | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** | **Gross Carrying Amount** | **Impairment Charges** <sup>(1)</sup> | **Accumulated Amortization** | **Net Carrying Amount** |
| Customer relationships | $17492 | $(7455) | $10037 | $17492 | $— | $(6232) | $11260 |
| Trade name | 2680 | (1429) | 1251 | 2680 |  | (1161) | 1519 |
| Proprietary software | 1042 | (680) | 362 | 1592 | (336) | (816) | 440 |
| Non-compete agreements | 1292 | (587) | 705 | 1292 |  | (445) | 847 |
| Vendor relationships | 20400 | (4344) | 16056 | 23700 | (2811) | (3700) | 17189 |
| &nbsp;&nbsp;**Total intangible assets** | $42906 | $(14495) | $28411 | $46756 | $(3147) | $(12354) | $31255 |

---

(1) During the year ended June 30, 2022, the Company recorded impairment charges for several of its long-lived intangible assets. Refer to the consolidated financial statements in our Annual Report on Form 10-K for additional details.

The Company's intangible assets include those long-lived intangible assets which were recognized at their estimated acquisition date fair values. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. There were no impairment triggers identified with respect to the Company's long-lived assets during the three and six months ended December 31, 2022 and 2021.

For the three months ended December 31, 2022 and 2021, amortization expense related to intangible assets totaled $1.4 million and $1.7 million, respectively, and $2.8 million and $3.3 million for the six months ended December 31, 2022 and 2021, respectively, recorded in selling, general, and administrative expense in the condensed consolidated statements of comprehensive income. The weighted-average remaining useful life of intangible assets was 5.7 and 6.2 years as of December 31, 2022 and June 30, 2022, respectively.

As of December 31, 2022, expected amortization expense in future fiscal periods were as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Trade Name** | **Proprietary Software** | **Non-Compete Agreements** | **Vendor Relationships** | **Customer relationships** | **Total** |
| Remainder fiscal 2023 | $268 | $78 | $131 | $1133 | $1162 | $2772 |
| 2024 | 536 | 156 | 220 | 2267 | 2319 | 5498 |
| 2025 | 447 | 128 | 220 | 2267 | 2316 | 5378 |
| 2026 |  |  | 134 | 2267 | 2313 | 4714 |
| 2027 |  |  |  | 2267 | 1927 | 4194 |
| Thereafter |  |  |  | 5855 |  | 5855 |
| **Total** | $1251 | $362 | $705 | $16056 | $10037 | $28411 |

---

***Goodwill—***The Company recorded as goodwill the excess of the purchase price over the estimated fair values of identifiable assets and liabilities acquired as part of the acquisitions discussed in Note 2 to the condensed consolidated financial statements. Goodwill is assigned to reporting units that are expected to benefit from the synergies of the business combination as of the acquisition date and becomes identified with that reporting unit in its entirety. As such, the reporting unit as a whole supports the recovery of its goodwill. As of December 31, 2022, the Company's goodwill balance of $29.1 million was related to the acquisitions of Express Meds and Simple Meds and is all assigned to the Healthcare Services reporting unit and reportable segment.

The Company performs its annual goodwill impairment testing as of April 1, or more frequently if it believes that indicators of impairment exist. During the three and six months ended December 31, 2022 and 2021, there were no indicators of impairment.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**6. LEASES**

The majority of the Company's leases are operating leases related to office space for which the Company recognizes lease expense on a straight-line basis over the respective lease term. The Company leases office facilities in the United States in San Diego, California; Centennial, Colorado; Overland Park, Kansas; Oakland, California; Indianapolis, Indiana; and Monaca, Pennsylvania (note that SelectRx leases the Monaca facility from an Executive Vice President of SelectRx. The Company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option that it is reasonably certain to exercise). The Company's operating leases have remaining lease terms of less than one year up to thirteen years.

During the six months ended December 31, 2022, operating leases commenced in San Diego, California and Indianapolis, Indiana, resulting in new right-of-use assets obtained in exchange for new lease liabilities of $1.6 million. In addition, the Company exercised an early termination option for a portion of its office facilities in Overland Park, Kansas, with a new termination date of July 31, 2023, resulting in an early termination penalty of $0.9 million. The early termination penalty was recorded as part of the remeasurement of the operating lease liability and resulted in accelerated amortization of the right-of-use asset over the shortened remaining term of the lease.

**Lease Costs**—The components of lease costs were as follows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** | **2022** | **2021** |
| Finance lease costs<sup>(1)</sup> | $42 | $42 | $86 | $84 |
| Operating lease costs<sup>(2)</sup> | 1953 | 2048 | 4045 | 4058 |
| Short-term lease costs | 32 | 15 | 63 | 28 |
| Variable lease costs<sup>(3)</sup> | 196 | 256 | 410 | 469 |
| Sublease income | (667) | (128) | (1085) | (465) |
| **Total net lease costs** | $1556 | $2233 | $3519 | $4174 |

---

(1) Primarily consists of amortization of finance lease right-of-use assets and an immaterial amount of interest on finance lease liabilities recorded in operating costs and expenses and interest expense, net in the condensed consolidated statements of comprehensive income.

(2) Recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.

(3) Variable lease costs are not included in the measurement of the lease liability or right-of-use asset as they are not based on an index or rate and primarily represents common area maintenance charges and real estate taxes recorded in operating costs and expenses in the condensed consolidated statements of comprehensive income.

**Maturities of Lease Liabilities**—As of December 31, 2022, remaining maturities of lease liabilities for each of the next five fiscal years and thereafter are as follows:

---

| | | | |
|:---|:---|:---|:---|
| *(in thousands)* | **Operating leases** | **Finance leases** | **Total** |
| Remainder fiscal 2023 | 5037 | 56 | 5093 |
| 2024 | 9151 | 38 | 9189 |
| 2025 | 8948 | 38 | 8986 |
| 2026 | 7412 | 38 | 7450 |
| 2027 | 6105 | 32 | 6137 |
| Thereafter | 14608 |  | 14608 |
| **&nbsp;&nbsp;&nbsp;&nbsp; Total undiscounted lease payments** | 51261 | 202 | 51463 |
| Less: interest | 13163 | 20 | 13183 |
| **&nbsp;&nbsp;&nbsp;&nbsp; Present value of lease liabilities** | $38098 | $182 | $38280 |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The Company executed noncancelable subleases for portions of its office facilities in Overland Park, Kansas and Centennial, Colorado, which commenced March 23, 2022; June 9, 2022; July 1, 2022; and September 2, 2022, and run through the remaining terms of the primary leases. Sublease income is recorded on a straight-line basis as a reduction of lease expense in the condensed consolidated statements of comprehensive income. The Company may consider entering into additional sublease arrangements in the future.

**Sublease Income**—As of December 31, 2022, the future minimum fixed sublease receipts under non-cancelable operating lease agreements are as follows:

---

| | |
|:---|:---|
| *(in thousands)* | **Total** |
| Remainder fiscal 2023 | $790 |
| 2024 | 2808 |
| 2025 | 3039 |
| 2026 | 2433 |
| 2027 | 2102 |
| Thereafter | 4024 |
| **Total sublease income** | $15196 |

---

**7. DEBT**

Debt consisted of the following:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | **December 31, 2022** | **June 30, 2022** |
| Term Loans (effective interest rate 13.3%) | $704873 | $713327 |
| Unamortized debt issuance costs and debt discount | (13354) | (7735) |
| **Total debt** | 691519 | 705592 |
| **Less current portion of long-term debt:** | (21400) | (7169) |
| **Long-term debt** | $670119 | $698423 |

---

**Senior Secured Credit Facility**— On November 5, 2019, the Company entered into a credit agreement with UMB Bank N.A. ("UMB") as a lender and revolving agent and Morgan Stanley Capital Administrators, Inc. as a lender and the administrative agent for a syndicate of lenders party to the agreement (replaced by Wilmington Trust as administrative agent effective February 24, 2022). On February 24, 2021, November 2, 2021, December 23, 2021, and August 26, 2022, the Company entered into amendments to the credit agreement (individually, the "First Amendment", "Second Amendment", "Third Amendment", and "Fourth Amendment", together with the original credit agreement and any subsequent amendments, the "Senior Secured Credit Facility") with certain of its existing lenders and new lenders. The First Amendment provided for an additional $231.0 million in term loans (together with the initial $425.0 million, the "Term Loans") and added a $145.0 million senior secured delayed draw term loan facility (the "DDTL Facility"). The Company recognized a $3.3 million loss on debt extinguishment in the condensed consolidated statement of comprehensive income for the year ended June 30, 2021, as part of the First Amendment. The Second Amendment provided for additional commitments of $25.0 million, in addition to the initial $75.0 million, for the secured revolving loan facility (the "Revolving Credit Facility") and an additional $200.0 million under the DDTL Facility. The Third Amendment provided for additional commitments of $35.0 million under the Revolving Credit Facility. The Fourth Amendment (1) amended the Company's existing financial covenant to better align with its business plan and added an additional minimum liquidity covenant, (2) terminated certain DDTL commitments and reduced the Revolving Credit Facility from $135.0 million to $100.0 million, (3) introduced a minimum asset coverage ratio for any borrowing on the Revolving Credit Facility that would result in a total revolving exposure of more than $50.0 million, and (4) provided certain lenders with the right to appoint a representative to observe meetings of the Company's board of directors and certain of its

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

committees. Note that pursuant to the Fourth Amendment, upon termination of the outstanding DDTL commitments, when referring to Term Loans, it will now include the outstanding balance of the previously defined Term Loans and also the outstanding balance of the DDTL, and "DDTL" will no longer be referenced. After giving effect to the amendments, in aggregate, the Senior Secured Credit Facility provides for (1) an aggregate principal amount of up to $100.0 million under the Revolving Credit Facility, of which all was available to borrow as of December 31, 2022 and (2) Term Loans outstanding in an aggregate principal amount of $704.9 million as of December 31, 2022.

Pursuant to the terms of the Fourth Amendment, each consenting lender received an amendment fee equal to 1.00% of the Term Loans held by such consenting lender and 0.50% of the Revolving Credit Facility commitments held by such consenting lender, in each case immediately after giving effect to the Fourth Amendment. In addition, the Fourth Amendment provides for the Company to pay a revolving credit termination fee of $0.5 million for the ratable account of each revolving lender upon the termination of all revolving loan commitments.

Following the Fourth Amendment, the Term Loans will bear interest on the outstanding principal amount thereof at a rate per annum equal to either (a) SOFR (subject to a floor of 0.75%) plus 6.00% in cash plus 2.00% payable in kind or (b) a base rate plus 5.00% in cash plus 2.00% payable in kind, at the Company's option. From and after October 1, 2023, the cash and paid in kind interest rate with respect to the Term Loans will rise 0.50% and 1.00% respectively. The Revolving Credit Facility will accrue interest on amounts drawn at a rate per annum equal to either (a) SOFR (subject to a floor of 1.0%) plus 5.0% or (b) a base rate plus 4.0%, at the Company's option.

The Senior Secured Credit Facility has a maturity date of November 5, 2024, and pursuant to the Fourth Amendment the Term Loans are mandatorily repayable in equal quarterly installments in an aggregate annual amount equal to 2.5% of the outstanding principal amount of the Term Loans as of the Fourth Amendment effective date, increasing to 4.75% on July 1, 2023, with the remaining balance payable on the maturity date. As of December 31, 2022, the Company has made total lifetime principal payments of $17.0 million on the Term Loans.

The Senior Secured Credit Facility contains customary affirmative and negative covenants and events of default and financial covenants requiring the Company and certain of its subsidiaries to maintain a minimum asset coverage ratio and minimum liquidity requirements. As of December 31, 2022, the Company was in compliance with all of the required covenants. The obligations of the Company are guaranteed by the Company's subsidiaries and secured by a security interest in all assets of the Company, subject to certain exceptions.

The Company has incurred a total of $40.1 million in debt issuance costs and debt discounts related to the Senior Secured Credit Facility, of which $33.0 million was capitalized. The costs associated with the Revolving Credit Facility are being amortized on a straight-line basis over the remaining life of the Senior Secured Credit Facility and the costs associated with the Term Loans are being amortized using the effective interest method over the same term. Total amortization of debt issuance costs was $2.3 million and $2.1 million for the three months ended December 31, 2022 and 2021, respectively, and $3.9 million and $3.0 million for the six months ended December 31, 2022 and 2021, respectively, which was included in interest expense, net in the Company's condensed consolidated statements of comprehensive income.

The Company uses derivative financial instruments to hedge against its exposure to fluctuations in interest rates associated with the Term Loans. On September 30, 2022, as a result of the Fourth Amendment, the Company terminated its existing interest rate swap indexed to 1-month LIBOR and executed a new interest rate swap indexed to 1-month SOFR. In accordance with ASC 848, *Reference Rate Reform*, the Company did not de-designate the interest rate swap when it was amended from LIBOR to SOFR as the Company is permitted to maintain the designation as part of the transitional relief. As of December 31, 2022, the Company's interest rate swap is a receive-variable, pay-fixed interest rate swap on the notional amount of $325.0 million of the Company's total outstanding Term Loans balance with a fixed rate of 6.00% plus 0.931% (the "Amended Interest Rate Swap"), which terminates on November 5, 2024. As of December 31, 2022, the Amended Interest Rate Swap had a fair value of $20.6 million and was recorded in other assets in the condensed consolidated balance sheet. The Company classifies its Amended Interest Rate Swap as a Level 2 on the fair value hierarchy as the majority of the inputs used to value it primarily includes other than quoted prices that are observable and it uses standard calculations and

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

models that use readily observable market data as their basis. The Company estimates that $12.4 million will be reclassified into interest expense during the next twelve months.

**8. COMMITMENTS AND CONTINGENCIES**

**Lease Obligations**—Refer to Note 6 to the condensed consolidated financial statements for commitments related to our operating leases.

**Legal Contingencies and Obligations**—From time to time, the Company is subject to legal proceedings and governmental inquiries in the ordinary course of business. Such matters may include insurance regulatory claims; commercial, tax, employment, or intellectual property disputes; matters relating to competition and sales practices; claims for damages arising out of the use of the Company's services. The Company may also become subject to lawsuits related to past or future acquisitions, divestitures, or other transactions, including matters related to representations and warranties, indemnities, and assumed or retained liabilities. The Company is not currently aware of any legal proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition, operating results, or cash flows; however, in the event of unexpected developments, it is possible that the ultimate resolution of certain ongoing matters, if unfavorable, could be materially adverse to our business, prospects, financial condition, liquidity, results of operation, cash flows, or capital levels.

***Securities Class Actions and Stockholder Derivative Suit***

On August 16, 2021, a putative securities class action lawsuit captioned *Hartel* v. *SelectQuote, Inc., et al.*, Case No. 1:21-cv-06903 ("the *Hartel* Action") was filed against the Company and two of its executive officers in the U.S. District Court for the Southern District of New York. The complaint asserts securities fraud claims on behalf of a putative class of plaintiffs who purchased or otherwise acquired shares of the Company's common stock between February 8, 2021 and May 11, 2021 (the "Hartel Relevant Period"). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company's business, operations, and prospects, allegedly causing the Company's common stock to trade at artificially inflated prices during the Hartel Relevant Period. The plaintiffs seek unspecified damages and reimbursement of attorneys' fees and certain other costs.

On October 7, 2021, a putative securities class action lawsuit captioned *West Palm Beach Police Pension Fund* v. *SelectQuote, Inc., et al.*, Case No. 1:21-cv-08279 ("the *WPBPPF* Action"), was filed in the U.S. District Court for the Southern District of New York against the Company, two of its executive officers, and six current or former members of the Company's Board of Directors, along with the underwriters of the Company's initial public offering of common stock (the "Offering"). The complaint asserts claims for securities law violations on behalf of a putative class of plaintiffs who purchased shares of the Company's common stock (i) in or traceable to the Offering or (ii) between May 20, 2020 and August 25, 2021 (the "WPB Relevant Period"). Specifically, the complaint alleges the defendants violated Sections 10(b) and 20(a) and Rule 10b-5 of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company's financial well-being and prospects, allegedly causing the Company's common stock to trade at artificially inflated prices during the WPB Relevant Period. The complaint also alleges the defendants violated Sections 11, 12(a)(2), and 15 of the Securities Act by making misstatements and omissions of material facts in connection with the Offering, allegedly causing a decline in the value of the Company's common stock. The plaintiffs seek unspecified damages, rescission, and reimbursement of attorneys' fees and certain other costs.

On October 15, 2021, a motion to consolidate the Hartel Action and the WPBPPF Action was filed. On September 2, 2022, the court entered an order consolidating the Hartel and WPBPPF Actions under the caption *In re SelectQuote, Inc. Securities Litigation*, Case No. 1:21-cv-06903 (the "Securities Class Action") and appointing the West Palm Beach Police Pension Fund and City of Fort Lauderdale Police & Fire Retirement System as lead plaintiffs. On November 19, 2022, plaintiffs filed an amended complaint asserting similar allegations to those alleged in the Hartel and WPBPPF Actions in addition to new allegations regarding certain defendants' purported

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

violation of Section 20A of the Exchange Act. The amended complaint also added Brookside Equity Partners LLC, one of the Company's principal stockholders, as a defendant. On January 27, 2023, the Company filed a motion to dismiss the amended complaint on behalf of itself and certain of its current and former officers and directors. That motion is pending before the court.

On March 25, 2022, a stockholder derivative action captioned *Jadlow* v. *Danker, et al.*, Case No. 1:22-cv-00391 ("the *Jadlow* Action") was filed in the U.S. District Court for the District of Delaware by an alleged stockholder of the Company, purportedly on the Company's behalf. The lawsuit was brought against certain of the Company's current and former directors and officers, and against the Company, as nominal defendant. The complaint alleges that certain of the defendants violated Section 14(a) of the Exchange Act by making materially false and misleading statements and failing to disclose material adverse facts about the Company's business, operations, and prospects. The complaint also asserts claims against all defendants for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets based on the same general underlying conduct and seeks contribution under Sections 10(b) and 21D of the Exchange Act and Section 11(f) of the Securities Act from the individual defendants named in the Securities Class Actions. The complaint seeks unspecified damages for the Company, restitution, reformation and improvement of its corporate governance and internal procedures regarding compliance with laws, and reimbursement of costs and attorneys' fees. On July 25, 2022, the *Jadlow* action was transferred to the U.S. District Court for the Southern District of New York, where it was assigned Case No. 1:22-cv-06290 and referred to Judge Alvin K. Hellerstein as possibly related to the *Hartel* Action. On August 4, 2022, Judge Hellerstein accepted the *Jadlow* action as related to the *Hartel* Action and, on August 10, 2022, granted the parties' joint stipulation to stay the *Jadlow* action pending the resolution of the motion to dismiss the Securities Class Action.

The Company currently believes that these matters will not have a material adverse effect on any of its results of operations, financial condition or liquidity; however, depending on how the matters progress, they could be costly to defend and could divert the attention of management and other resources from operations. The Company has not concluded that a loss related to these matters is probable and, therefore, has not accrued a liability related to these matters.

**9. SHAREHOLDERS' EQUITY**

**Common Stock**—As of December 31, 2022, the Company has reserved the following authorized, but unissued, shares of common stock:

---

| | |
|:---|:---|
| Employee Stock Purchase Plan | 97146 |
| Stock awards outstanding under 2020 Plan | 12625040 |
| Stock awards available for grant under 2020 Plan | 6400291 |
| Options outstanding under 2003 Plan | 562504 |
| **Total** | 19684981 |

---

**Share-Based Compensation Plans**

The Company has awards outstanding from two share-based compensation plans: the 2003 Stock Incentive Plan (the "2003 Stock Plan") and the 2020 Omnibus Incentive Plan (the "2020 Stock Plan" and, collectively with the 2003 Stock Plan, the "Stock Plans"). However, no further awards will be made under the 2003 Stock Plan. The Company's Board of Directors adopted, and shareholders approved, the 2020 Stock Plan in connection with the IPO, which provides for the grant of incentive stock options ("ISO's"), nonstatutory stock options ("NSO's"), stock appreciation rights, restricted stock awards, restricted stock unit awards ("RSU's"), performance-based restricted stock units ("PSU's"), price-vested restricted stock units ("PVU's"), and other forms of equity compensation (collectively, "stock awards"). All awards (other than ISOs, which may be granted only to current employees of the Company) may be granted to employees, non-employee directors, and consultants of the Company and its subsidiaries and affiliates.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The number of shares of common stock available for issuance as of December 31, 2022, pursuant to future awards under the Company's 2020 Stock Plan is 6,400,291. The number of shares of the Company's common stock reserved under the 2020 Stock Plan is subject to an annual increase on the first day of each fiscal year, beginning on July 1, 2021, equal to 3% of the total outstanding shares of common stock as of the last day of the immediately preceding fiscal year. The maximum number of shares of common stock that may be issued upon the exercise of ISO's will be 4,000,000. The shares of common stock covered by any award (including any award granted pursuant to the 2003 Stock Plan) that is forfeited, terminated, expired, or lapsed without being exercised or settled for cash will again become available for issuance under the 2020 Stock Plan. With respect to any award, if the exercise price and/or tax withholding obligations are satisfied by delivering shares to the Company (by actual delivery or attestation), or if the exercise price and/or tax withholding obligations are satisfied by withholding shares otherwise issuable pursuant to the award, the share reserve shall nonetheless be reduced by the gross number of shares subject to the award.

The Company accounts for its share-based compensation awards in accordance with ASC 718, *Compensation—Stock Compensation* ("ASC 718") which requires all share-based compensation to be recognized in the income statement based on fair value and applies to all awards granted, modified, canceled, or repurchased after the effective date.

Total share-based compensation for stock awards included in selling, general, and administrative expense in the condensed consolidated statements of comprehensive income was as follows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** | **2022** | **2021** |
| Share-based compensation related to: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity classified stock options | $844 | $884 | $1696 | $1624 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity classified RSU's | 1525 | 1127 | 2927 | 2080 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity classified PSU's | 9 | (305) | (48) | 87 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity classified PVU's | 539 |  | $897 |  |
| **Total** | $2917 | $1706 | $5472 | $3791 |

---

**Stock Options**—The stock options outstanding under the 2003 Stock Plan vest as to one-third after the vesting commencement date and as to 1/24 of the remaining shares subject to the stock option monthly thereafter, subject to the award recipient's continued employment through the applicable vesting date. Upon a termination of employment for any reason other than for "Cause" (as defined in the 2003 Stock Plan), any unvested and outstanding stock options would generally be forfeited for no consideration, and any vested and outstanding stock options would remain exercisable for 90 days following the date of termination (and, in the case of a termination of employment due to death or disability, for 12 months following the date of termination). Stock options expire 10 years from the date of grant. The terms for ISO's and NSO's awarded in the 2020 Stock Plan are the same as in the 2003 Stock Plan with the exception that the options generally shall vest and become exercisable in four equal installments on each of the first four anniversaries of the grant date, subject to the award recipient's continued employment through the applicable vesting date. Stock options are granted with an exercise price that is no less than 100% of the fair market value of the underlying shares on the date of the grant.

The fair value of each option (for purposes of calculation of share-based compensation expense) is estimated using the Black-Scholes-Merton option pricing model that uses assumptions determined as of the date of the grant. Use of this option pricing model requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them ("expected term"), the estimated volatility of the Company's common stock price over the expected term ("volatility"), the number of options that will ultimately not complete their vesting requirements ("assumed forfeitures"), the risk-free interest rate that reflects the interest rate at grant date on zero-coupon United States governmental bonds that have a

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

remaining life similar to the expected term ("risk-free interest rate"), and the dividend yield assumption which is based on the Company's dividend payment history and management's expectations of future dividend payments ("dividend yield"). Changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the condensed consolidated statements of comprehensive income.

During the six months ended December 31, 2022, there were no stock options granted. The Company used the following weighted-average assumptions for the stock options granted during the six months ended December 31, 2021:

---

| | |
|:---|:---|
| | **Six Months Ended December 31,** |
| | **2021** |
| Volatility | 30.2% |
| Risk-free interest rate | 0.9% |
| Dividend yield | —% |
| Assumed forfeitures | —% |
| Expected term (in years) | 6.25 |
| Weighted-average fair value (per share) | $5.52 |

---

The following table summarizes stock option activity under the Stock Plans for the six months ended December 31, 2022:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of Options** | **Weighted- Average Exercise Price** | **Weighted- Average Remaining Contractual Term (in Years)** | **Aggregate Intrinsic Value (in Thousands)** |
| Outstanding—June 30, 2022 | 5211585 | $9.14 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options granted |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options exercised | (1116624) | 0.53 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options forfeited/expired/cancelled | (128645) | 12.32 |  |  |
| Outstanding—December 31, 2022 | 3966316 | $11.47 | 7.95 | $2 |
| Vested and exercisable—December 31, 2022 | 1446136 | $12.32 | 6.76 | $2 |

---

As of December 31, 2022, there was $6.7 million in unrecognized compensation cost related to unvested stock options granted, which is expected to be recognized over a weighted-average period of 2.35 years.

The Company received cash of $0.0 million and $0.1 million in connection with stock options exercised during the three months ended December 31, 2022 and 2021, respectively, and $1.1 million and $2.3 million in connection with stock options exercised during the six months ended December 31, 2022 and 2021, respectively.

**Restricted Stock**—The Company grants RSU's to eligible employees, non-employee directors, and contractors. These awards generally vest over a period of one to four years. Fair value of the RSU's is determined based on the market price of the Company's common stock at the grant date and share-based compensation expense is recognized over the requisite service period.

The following table summarizes restricted stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2022:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | |
|:---|:---|:---|
| | **Number of Restricted Stock Units** | **Weighted-Average Grant Date Fair Value** |
| Unvested as of June 30, 2022 | 810310 | $13.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | 4321972 | 1.47 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | (181424) | 15.80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (157925) | 4.14 |
| Unvested as of December 31, 2022 | 4792933 | $2.87 |

---

As of December 31, 2022, there was $11.0 million of unrecognized compensation cost related to unvested restricted stock units granted, which is expected to be recognized over a weighted-average period of 2.24 years.

**Performance Stock**—The following table summarizes performance stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2022:

---

| | | |
|:---|:---|:---|
| | **Number of Performance Stock Units** | **Weighted-Average Grant Date Fair Value** |
| Unvested as of June 30, 2022<sup>(1)</sup> | 13293 | $17.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted<sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (5236) | 18.58 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance adjustment<sup>(2)</sup> | (2488) |  |
| Unvested as of December 31, 2022 | 5569 | $17.96 |

---

(1) Reflects PSU's at 100% achievement of predefined financial performance targets. If performance metrics are met, PSU's will vest, at the end of a three-year performance period. The number of shares that could be earned for the fiscal year 2021 tranche will range from 0% to 150% of the target, and the number of shares that could be earned for the fiscal year 2022 tranche will range from 0% to 200% of the target.

(2) Represents adjustments to previously granted PSU's to reflect changes in estimates of future financial performance against targets.

As of December 31, 2022, there was less than $0.1 million of unrecognized compensation cost related to unvested performance stock units granted, which is expected to be recognized over a weighted-average period of 0.66 years.

**Price-Vested Units**—During the six months ended December 31, 2022 the Company issued PVU's for which vesting is subject to the fulfillment of both a service period and the achievement of stock price hurdles during the relevant performance period. The awards are divided into four separate tranches, each with a different price hurdle which is measured as the average trading price over 60 calendar days on a rolling daily basis, over a performance period of five years. An employee is eligible to vest in one-third of the awards in each tranche after each year of service, but subject to the achievement of the stock-price hurdle attached to each tranche. As a result, share-based compensation will be recognized on a straight-line basis across twelve tranches over each tranche's requisite service period, which is the greater of the derived service period and the explicit service period. The number of shares subject to each tranche of the PVU awards, as well as the stock price hurdles, service periods, and performance periods for each tranche are as follows:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Number of Shares per Tranche** | **Grant Date Fair Value (per Share)** | **Stock Price Hurdle (per Share)** | **Performance Period** | **Requisite Service Period** |
| Tranche 1 | 1055674 | $1.52 | $4.00 | August 1, 2022 - August 1, 2027 | 1.39 years - 3 years |
| Tranche 2 | 1055648 | $1.25 | $7.50 | August 1, 2022 - August 1, 2027 | 2.33 years - 3 years |
| Tranche 3 | 1055674 | $1.11 | $10.00 | August 1, 2022 - August 1, 2027 | 2.66 years - 3 years |
| Tranche 4 | 1055648 | $1.01 | $12.50 | August 1, 2022 - August 1, 2027 | 2.90 years - 3 years |

---

The fair value of each PVU (for purposes of calculation of share-based compensation expense) is estimated using a Monte Carlo simulation valuation model that uses assumptions determined as of the date of the grant. Use of this model requires the input of subjective assumptions and changes in the subjective assumptions can materially affect the estimate of the fair value of share-based compensation and, consequently, the related amount recognized in the condensed consolidated statements of comprehensive income.

During the six months ended December 31, 2021, there were no PVU's granted. The Company used the following weighted-average assumptions for the PVU's granted during the six months ended December 31, 2022:

---

| | |
|:---|:---|
| | **Six Months Ended December 31,** |
| | **2022** |
| Share price as of grant date | $1.80 |
| Volatility | 79.3% |
| Risk-free interest rate | 2.6% |
| Cost of Equity | 10.6% |
| Dividend yield | —% |

---

The following table summarizes price-vested stock unit activity under the 2020 Stock Plan for the six months ended December 31, 2022:

---

| | | |
|:---|:---|:---|
| | **Number of Price-Vested Units** | **Weighted-Average Grant Date Fair Value** |
| Unvested as of June 30, 2022 |  | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | 4222644 | 1.22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (72462) | 1.22 |
| Unvested as of December 31, 2022 | 4150182 | $1.22 |

---

As of December 31, 2022, there was $4.2 million of unrecognized compensation cost related to unvested PVU's granted, which is expected to be recognized over a weighted-average period of 2.16 years.

**ESPP**—The purpose of the Company's employee stock purchase plan ("ESPP") is to provide the Company's eligible employees with an opportunity to purchase shares on the exercise date at a price equal to 85% of the fair market value of the Company's common stock as of either the exercise date or the first day of the relevant

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

offering period, whichever is lesser. During the six months ended December 31, 2022, and 2021, the Company issued 779,946 and 89,985 shares, respectively, to its employees, and as of December 31, 2022, there are 97,146 shares reserved for future issuance under the plan. The Company recorded share-based compensation expense related to the ESPP of less than $0.1 million and $0.2 million for the three months ended December 31, 2022 and 2021, respectively, and recorded share-based compensation expense of $0.1 million and $0.3 million with respect to the ESPP for the six months ended December 31, 2022 and 2021, respectively.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**10. REVENUES FROM CONTRACTS WITH CUSTOMERS**

**Disaggregation of Revenue from Contracts with Customers**—The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** | **2022** | **2021** |
| **Senior:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare advantage | $190479 | $99262 | $256836 | $179345 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare supplement | 1056 | 2332 | 1171 | 3936 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prescription drug plan | 187 | 732 | 278 | 1001 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dental, vision, and health | 1682 | 4920 | 2018 | 8136 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other commission revenue | 779 | 2758 | 1435 | 3926 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 194183 | 110004 | 261738 | 196344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 29643 | 37690 | 39602 | 51955 |
| **Total Senior revenue** | 223826 | 147694 | 301340 | 248299 |
| **Healthcare Services:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total pharmacy revenue | 51601 | 8770 | 92694 | 13237 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 3879 | 2307 | 5852 | 3823 |
| **Total Healthcare Services revenue** | 55480 | 11077 | 98546 | 17060 |
| **Life:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term | 16317 | 16126 | 31693 | 32372 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Final expense | 13134 | 10142 | 30553 | 33281 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 29451 | 26268 | 62246 | 65653 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 4544 | 5768 | 8584 | 12366 |
| **Total Life revenue** | 33995 | 32036 | 70830 | 78019 |
| **Auto & Home:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 7364 | 5657 | 14045 | 12649 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 444 | 478 | 845 | 955 |
| **Total Auto & Home revenue** | 7808 | 6135 | 14890 | 13604 |
| **Eliminations:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | (965) | (1972) | (1661) | (3882) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | (956) | (733) | (2273) | (2784) |
| **Total Elimination revenue** | (1921) | (2705) | (3934) | (6666) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 230033 | 139957 | 336368 | 270764 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total pharmacy revenue | 51601 | 8770 | 92694 | 13237 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 37554 | 45510 | 52610 | 66315 |
| **Total revenue** | $319188 | $194237 | $481672 | $350316 |

---

**Contract Balances**—The Company has contract assets related to commissions receivable from its insurance carrier partners, with the movement over time as the policy is renewed between long-term and short-term

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

commissions receivable and accounts receivable, net being the main activity, along with commission revenue adjustments from changes in estimates.

A roll forward of commissions receivable (current and long-term) is shown below for the period presented:

---

| | |
|:---|:---|
| *(in thousands)* |  |
| **Balance as of June 30, 2022** | $838626 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue from revenue recognized | 139587 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net commission revenue adjustment from change in estimate | 619 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts recognized as accounts receivable, net | (25505) |
| **Balance as of December 31, 2022** | $953327 |

---

For the six months ended December 31, 2022, the $0.6 million net commission revenue adjustment from change in estimate includes adjustments from the Company's reassessment of each of its cohorts' transaction prices.

The Company's contract liabilities on the condensed consolidated balance sheet represent unamortized upfront payments received as of December 31, 2022, for commission revenue of $37.6 million and marketing development funds of $1.2 million for which the performance obligations have not yet been met and are anticipated to be recognized over the next twelve months.

A roll forward of contract liabilities (current) is shown below for the period presented:

---

| | |
|:---|:---|
| *(in thousands)* |  |
| **Balance as of June 30, 2022** | $3404 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue from revenue recognized | (11029) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other revenue from revenue recognized | (24736) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts recognized as contract liabilities | 71113 |
| **Balance as of December 31, 2022** | $38752 |

---

**11. INCOME TAXES**

For the three months ended December 31, 2022 and 2021, the Company recognized income tax expense of $9.4 million and income tax benefit of $46.7 million, respectively, representing effective tax rates of 29.5% and 25.4%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2022, were primarily related to state income taxes, RSU vestings, and the recording of a valuation allowance for state tax attributes that the Company does not expect to utilize prior to expiration. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2021, were primarily related to state income taxes.

For the six months ended December 31, 2022 and 2021, the Company recognized income tax benefits of $4.2 million and $63.1 million, respectively, representing effective tax rates of 17.4% and 25.4%, respectively. The differences from the federal statutory tax rate to the effective tax rate for the six months ended December 31, 2022, were primarily related to state income taxes, RSU vestings, and the recording of a valuation allowance for state tax attributes that the Company does not expect to utilize prior to expiration. The differences from the federal statutory tax rate to the effective tax rate for the six months ended December 31, 2021, were primarily related to state income taxes.

Assessing the realizability of the Company's deferred tax assets is dependent upon several factors, including analysis of the Company's four sources of future taxable income listed under ASC 740, *Income Taxes*.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The Company continues to evaluate the realizability of its net deferred tax assets. As of December 31, 2022, the Company recorded a valuation allowance on deferred tax balances related to state tax attributes the Company determined would not be utilized prior to expiration. The Company believes all other deferred tax assets are more likely than not to be recognized.

**12. NET INCOME (LOSS) PER SHARE**

The Company calculates net income (loss) per share as defined by ASC 260, *Earnings per Share* ("ASC 260"). Basic net income (loss) per share ("Basic EPS") is computed by dividing net income (loss) attributable to common shareholders by the weighted-average common stock outstanding during the respective period. Diluted net income (loss) per share ("Diluted EPS") is computed by dividing net income (loss) attributable to common and common equivalent shareholders by the total of the weighted-average common stock outstanding and common equivalent shares outstanding during the respective period. For the purpose of calculating the Company's Diluted EPS, common equivalent shares outstanding include common shares issuable upon the exercise of outstanding employee stock options, unvested RSU's, PSU's assuming the performance conditions are satisfied as of the end of the reporting period, PVU's assuming market conditions are satisfied as of the end of the reporting period, and common shares issuable upon the conclusion of each ESPP offering period. The number of common equivalent shares outstanding has been determined in accordance with the treasury stock method for employee stock options, RSU's, PSU's, PVU's, and common stock issuable pursuant to the ESPP to the extent they are dilutive. Under the treasury stock method, the exercise price paid by the option holder and future share-based compensation expense that the Company has not yet recognized are assumed to be used to repurchase shares.

The following table sets forth the computation of net income (loss) per share for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands, except per share amounts)* | **2022** | **2021** | **2022** | **2021** |
| **Basic:** |  |  |  |  |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to common shareholders | $22514 | $(137563) | $(19970) | $(185795) |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average common stock outstanding | 166486 | 163966 | 165655 | 163829 |
| **Net income (loss) per share—basic:** | $0.14 | $(0.84) | $(0.12) | $(1.13) |
| **Diluted:** |  |  |  |  |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to common and common equivalent shareholders | $22514 | $(137563) | $(19970) | $(185795) |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average common stock outstanding | 166486 | 163966 | 165655 | 163829 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP<sup>(1)(2)</sup> | 62 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total common and common equivalent shares outstanding | 166548 | 163966 | 165655 | 163829 |
| **Net income (loss) per share—diluted:** | $0.14 | $(0.84) | $(0.12) | $(1.13) |

---

(1) Excluded from the computation of net income (loss) per share-diluted for the six months ended December 31, 2022, because the effect would have been anti-dilutive.

(2) Excluded from the computation of net income (loss) per share-diluted for the three and six months ended December 31, 2021, because the effect would have been anti-dilutive.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted because including them would have been anti-dilutive are as follows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** | **2022** | **2021** |
| &nbsp;&nbsp;Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP | 8268 | 5133 | 8061 | 4908 |

---

The weighted average potential shares of common stock that were excluded from the calculation of net income (loss) per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** | **2022** | **2021** |
| &nbsp;&nbsp;Shares subject to outstanding PVU's | 4150 |  | 4186 |  |
| &nbsp;&nbsp;Shares subject to outstanding PSU's | 6 | 165 | 6 | 247 |
| &nbsp;&nbsp;**Total** | 4156 | 165 | 4192 | 247 |

---

**13. SEGMENT INFORMATION**

The Company's operating and reportable segments have been determined in accordance with ASC 280, *Segment Reporting* ("ASC 280"). Prior to the first quarter of fiscal 2023, the Company had reported financial results under three reportable segments: i) Senior, ii) Life, and iii) Auto & Home. Effective July 1, 2022, as a result of a change in strategic direction established for fiscal year 2023, the financial information available and the operating results that are regularly reviewed by the Company's chief operating decision maker ("CODM") to make decisions about resources to be allocated to the segments and assess its performance have also changed with the financial information related to Healthcare Services, which includes SelectRx and Population Health, now available and reviewed by our CODM separately from the remainder of the Senior reportable segment. As a result, the Company now reflects four reportable segments: i) Senior, ii) Healthcare Services, iii) Life, and iv) Auto & Home, and all prior periods have been restated to reflect four reportable segments.

The Company includes non-operating activity, share-based compensation expense, certain intersegment eliminations, and the costs of providing corporate and other administrative services in its administrative division in Corporate & Eliminations. These services and activities are not directly identifiable with the Company's reportable segments and are shown in the tables below to reconcile the reportable segments to the condensed consolidated financial statements. The Company has not aggregated any operating segments into a reportable segment.

Costs of revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, cost of goods sold, marketing and advertising, technical development, and selling, general, and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; and non-recurring expenses such as severance payments and transaction costs. Our CODM does not separately evaluate assets by segment; therefore, assets by segment are not presented.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The following table presents information about the reportable segments for the three months ended December 31, 2022:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $223826 | $55480 | $33995 | $7808 | $(1921) | (1) | $319188 |
| Operating expenses | (140209) | (64781) | (28152) | (5524) | (16877) | (2) | (255543) |
| Other income (expense), net |  |  |  |  | (70) |  | (70) |
| **Adjusted EBITDA** | $83617 | $(9301) | $5843 | $2284 | $(18868) |  | 63575 |
| Share-based compensation expense |  |  |  |  |  |  | (2936) |
| Transaction costs<sup>(3)</sup> |  |  |  |  |  |  | (442) |
| Depreciation and amortization |  |  |  |  |  |  | (7188) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (46) |
| Interest expense, net |  |  |  |  |  |  | (21044) |
| Income tax expense |  |  |  |  |  |  | (9405) |
| **Net income** |  |  |  |  |  |  | $22514 |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $12.2 million in salaries and benefits for certain general, administrative, and IT related departments and $4.6 million in professional services fees.

(3) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility and non-restructuring severance expenses.

The following table presents information about the reportable segments for the three months ended December 31, 2021:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $147694 | $11077 | $32036 | $6135 | $(2705) | (1) | $194237 |
| Operating expenses | (287914) | (19492) | (30930) | (4700) | (15175) | (2) | (358211) |
| Other expenses, net |  |  |  |  | (51) |  | (51) |
| **Adjusted EBITDA** | $(140220) | $(8415) | $1106 | $1435 | $(17931) |  | (164025) |
| Share-based compensation expense |  |  |  |  |  |  | (1894) |
| Non-recurring expenses <sup>(3)</sup> |  |  |  |  |  |  | (1602) |
| Depreciation and amortization |  |  |  |  |  |  | (6175) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (5) |
| Interest expense, net |  |  |  |  |  |  | (10587) |
| Income tax benefit |  |  |  |  |  |  | 46725 |
| **Net loss** |  |  |  |  |  |  | $(137563) |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments primarily for referrals from Senior to the other segments.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

(2) Operating expenses in the Corp & Elims division primarily include $11.2 million in salaries and benefits for certain general, administrative, and IT related departments and $4.3 million in professional services fees.

(3) These expenses primarily consist of debt issuance costs incurred for the Second Amendment.

The following table presents information about the reportable segments for the six months ended December 31, 2022:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $301340 | $98546 | $70830 | $14890 | $(3934) | (1) | $481672 |
| Operating expenses | (221574) | (119635) | (59963) | (10164) | (34322) | (2) | (445658) |
| Other income (expense), net |  |  | 201 | (1) | (112) |  | 88 |
| **Adjusted EBITDA** | $79766 | $(21089) | $11068 | $4725 | $(38368) |  | 36102 |
| Share-based compensation expense |  |  |  |  |  |  | (5566) |
| Transaction costs<sup>(3)</sup> |  |  |  |  |  |  | (2570) |
| Depreciation and amortization |  |  |  |  |  |  | (13990) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (371) |
| Interest expense, net |  |  |  |  |  |  | (37780) |
| Income tax benefit |  |  |  |  |  |  | 4205 |
| **Net loss** |  |  |  |  |  |  | $(19970) |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $24.3 million in salaries and benefits for certain general, administrative, and IT related departments and $9.2 million in professional services fees.

(3) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility.

The following table presents information about the reportable segments for the six months ended December 31, 2021:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $248299 | $17060 | $78019 | $13604 | $(6666) | (1) | $350316 |
| Operating expenses | (417560) | (29405) | (76058) | (10796) | (28258) | (2) | (562077) |
| Other expenses, net |  |  |  |  | (153) |  | (153) |
| **Adjusted EBITDA** | $(169261) | $(12345) | $1961 | $2808 | $(35077) |  | (211914) |
| Share-based compensation expense |  |  |  |  |  |  | (4109) |
| Non-recurring expenses <sup>(3)</sup> |  |  |  |  |  |  | (2155) |
| Depreciation and amortization |  |  |  |  |  |  | (11278) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (355) |
| Interest expense, net |  |  |  |  |  |  | (19122) |
| Income tax benefit |  |  |  |  |  |  | 63138 |
| **Net loss** |  |  |  |  |  |  | $(185795) |

---

1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments primarily for lead generation referrals from InsideResponse (within Senior) to the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $21.6 million in salaries and benefits for certain general, administrative, and IT related departments, and $9.0 million in professional services fees.

(3) These expenses primarily consist of costs incurred for the Second Amendment and costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds.

Revenues from each of the reportable segments are earned from transactions in the United States and follow the same accounting policies used for the Company's condensed consolidated financial statements. All of the Company's long-lived assets are located in the United States. For the three months ended December 31, 2022, two customers, which provided revenue to both Senior and Healthcare Services, accounted for 27% and 22% of total revenue. For the three months ended December 31, 2021, three insurance carrier customers from Senior accounted for 24%, 15%, and 11% of total revenue, respectively. For the six months ended December 31, 2022, two customers, which provided revenue to both Senior and Healthcare Services, accounted for 23% and 17% of total revenue. For the six months ended December 31, 2021, three insurance carrier customers from Senior accounted for 21%, 14%, and 13% of total revenue, respectively.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*You should read the following discussion and analysis of our financial condition and result of operations together with our condensed consolidated financial statements and footnotes included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions, and projections about our industry, business and future financial results. Please refer to a discussion of the Company's forward-looking statements and associated risks in "Cautionary Note Regarding Forward-Looking Statements" in our 2022 Annual Report. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled "Risk Factors" in our 2022 Annual Report and in Part II, Item 1A hereof.*

**Correction of Previously Issued Condensed Consolidated Financial Statements**

Subsequent to the issuance of the Company's financial statements as of and for the year ended June 30, 2021, the Company determined that the provision for first year commission revenue for certain final expense policies offered by certain of its insurance carrier partners should have been accrued based on a higher lapse rate.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

This misstatement was initially thought to be isolated to an error in the lapse rate for one of its insurance carrier partners, as disclosed in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2021. However, during the three months ended June 30, 2022, it was determined that the lapse rate for other insurance carrier partners were also incorrect, resulting in an additional misstatement being identified. See Note 1 to the condensed consolidated financial statements for additional information related to the correction, including descriptions of the misstatements and the impacts to our condensed consolidated financial statements. In addition, we have corrected certain previously reported financial information for the three and six months ended December 31, 2021, in this Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.

**Company Overview**

*Our Business.* We are a leading technology-enabled, direct-to-consumer ("DTC") distribution platform for insurance products and healthcare services. Our insurance distribution business, which has operated continuously for over 35 years, provides consumers with a transparent and convenient venue to shop for complex senior health, life, and automobile and home insurance policies from a curated panel of the nation's leading insurance carriers. As an insurance distributor, we do not insure the consumer, but rather identify consumers looking to acquire insurance products and place these consumers with insurance carrier partners that provide these products. In return, we earn commissions from our insurance carrier partners for the policies we sell on their behalf. Our proprietary technology allows us to take a broad funnel approach to marketing by analyzing and identifying high-quality consumer leads sourced from a wide variety of online and offline marketing channels including search engines, radio, television, and third-party marketing partners. We monitor our acquisition costs to dynamically allocate our marketing spend to the most attractive channels, benefiting from over thirty years of data accumulated through our proprietary, purpose-built technologies. Our advanced workflow processing system scores each acquired lead in real time, matching it with a sales agent whom we determine is best suited to meet the consumer's need. Our platform then captures and utilizes our experience to further build upon the millions of data points that feed our marketing algorithms, further enhancing our ability to deploy subsequent marketing dollars efficiently and target more high-quality consumer leads. We have built our business model to maximize commissions collected over the life of an approved policy less the cost of acquiring the business, a metric we refer to as policyholder lifetime value and which is a key component to our overall profitability.

Our unique platform has enabled us to expand our distribution business in recent years to include additional products beyond insurance policies. In interacting with thousands of consumers over the years, we identified a large opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers. In addition to improving consumers' health outcomes, this service creates deeper relationships with our insurance carrier partners by increasing policy persistency and, in turn, reducing their overall costs. Additionally, we offer pharmacy services through our closed-door, long-term care pharmacy, which offers essential prescription medications, OTC medications, customized medication packaging, medication therapy management, and other consultative services.

We evaluate our business using the following four segments:

Senior was launched in 2010 and provides unbiased comparison shopping for Medicare Advantage ("MA") and Medicare Supplement ("MS") insurance plans as well as prescription drug and dental, vision, and hearing ("DVH") plans, and critical illness products. We represent approximately 21 leading, nationally-recognized insurance carrier partners, including UnitedHealthcare, Humana, and Wellcare. MA and MS plans accounted for 91% and 84% of our approved Senior policies for the three months ended December 31, 2022 and 2021, respectively, and 90% and 82% for the six months ended December 31, 2022 and 2021, respectively, with other ancillary type policies accounting for the remainder.

Healthcare Services, launched in 2021, includes SelectRx and Population Health, and was previously included under the Senior segment (refer to Note 13 to the condensed consolidated financial statements for further information on the change in segments). Through SelectRx, we provide simple solutions for prescription drug management and support with a personalized approach to streamline the process of managing multiple medications for seniors with chronic conditions. SelectRx has developed a pill pack solution that is customized to the unique

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

needs of each patient, focusing on individual multi-dosages by day and time. SelectRx uses a high-touch, technology-driven approach to provide superior customer service and achieve improved medication adherence. Population Health contracts with insurance carriers to perform health risk assessments ("HRA") on potential new members to determine how Population Health's value-based care ("VBC") partners can help members improve health outcomes. Consumers receive one-on-one assistance from our customer success agents who help patients understand the benefits available under their health plans and connect them with additional healthcare related resources. We believe that offering these services through SelectRx and Population Health to our existing MA consumers helps drive customer satisfaction and increase policy persistency, which, in turn, reduces costs for our insurance carrier partners.

Life is one of the country's largest and most established DTC insurance distributors for term life insurance, having sold over 2.1 million policies nationwide since our founding in 1985. Our platform provides unbiased comparison shopping for life insurance products such as term life, final expense, and other ancillary products like critical illness, accidental death, and juvenile insurance. We represent approximately 22 leading, nationally-recognized insurance carrier partners, with many of these relationships exceeding 15 years. Term life policies accounted for 48% and 42% of new premium within Life for the three months ended December 31, 2022 and 2021, respectively, with final expense policies accounting for 52% and 58% for the three months ended December 31, 2022 and 2021, respectively. For the six months ended December 31, 2022 and 2021, term life policies accounted for 44% and 36% of new premium within Life, respectively, with final expense policies accounting for 56% and 64%, respectively.

Auto & Home was launched in 2011 as an unbiased comparison shopping platform for auto, home, and specialty insurance lines. Our platform provides unbiased comparison shopping for insurance products such as homeowners, auto, dwelling fire, and other ancillary insurance products underwritten by approximately 22 leading, nationally-recognized insurance carrier partners. Homeowners and 12-month auto products accounted for 73% and 76% of new premium within Auto & Home for the three months ended December 31, 2022 and 2021, respectively, and 74% and 76% for the six months ended December 31, 2022 and 2021, respectively, with six-month auto, dwelling fire, and other products accounting for a majority of the remainder.

The three and six months ended December 31 referenced throughout the commentary below refers to the second quarter and fiscal year-to-date performance of our fiscal years ending on June 30, 2023 and 2022.

**Key Business and Operating Metrics by Segment**

In addition to traditional financial metrics, we rely upon certain business and operating metrics to estimate and recognize revenue, evaluate our business performance, and facilitate our operations. In Senior, our primary product, Medicare Advantage, pays us flat commission rates based on the number of policies we sell on behalf of our insurance carrier partners. Therefore, we have determined that units and unit metrics are the most appropriate measures to evaluate the performance of Senior. For Healthcare Services, our primary source of revenue is pharmacy revenue from SelectRx, so the total number of SelectRx members is the most appropriate measure used to evaluate the performance of Healthcare Services. In Life and Auto & Home, we are typically paid a commission that is a percent of the premium that we generate for our insurance carrier partners. Therefore, we have determined that premium-based metrics are the most relevant measures to evaluate the performance of these segments. Below are the most relevant business and operating metrics for each segment:

**Senior**

***Submitted Policies***

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to them to submit it to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Medicare Advantage | 251847 | 340317 | 341875 | 436106 |
| Medicare Supplement | 1565 | 3117 | 2230 | 4929 |
| Dental, Vision, and Hearing | 22004 | 53432 | 38338 | 82036 |
| Prescription Drug Plan | 1302 | 4241 | 1666 | 5114 |
| Other | 1512 | 2967 | 3538 | 6529 |
| **Total** | 278230 | 404074 | 387647 | 534714 |

---

Total submitted policies for all products decreased 31% for the three months ended December 31, 2022, compared to the three months ended December 31, 2021, in line with our updated operating strategy to reduce the Senior distribution business and focus resources on Healthcare Services. The number of average productive agents decreased 63% during the three months ended December 31, 2022, compared to the three months ended December 31, 2021; however, due to a higher mix of tenured agents and an increased focus on agent training and development, productivity per agent increased 89% and overall close rates increased 54%.

Total submitted policies for all products decreased 28% for the six months ended December 31, 2022, compared to the six months ended December 31, 2021, in line with our updated operating strategy to reduce the Senior distribution business and focus resources on Healthcare Services. The number of average productive agents decreased 51% during the six months ended December 31, 2022, compared to the six months ended December 31, 2021; however, due to a higher mix of tenured agents and an increased focus on agent training and development, productivity per agent increased 45% and overall close rates increased 38%.

***Approved Policies***

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Medicare Advantage | 218837 | 265538 | 302010 | 349654 |
| Medicare Supplement | 1127 | 2097 | 1627 | 3495 |
| Dental, Vision and Hearing | 18697 | 44542 | 30972 | 66765 |
| Prescription Drug Plan | 883 | 3352 | 1273 | 4220 |
| Other | 1241 | 2483 | 2903 | 5363 |
| **Total** | 240785 | 318012 | 338785 | 429497 |

---

In general, the relationship between submitted policies and approved policies has been steady over time. Therefore, factors impacting the number of submitted policies also impact the number of approved policies.

Total approved policies for all products decreased 24% for the three months ended December 31, 2022, compared to the three months ended December 31, 2021, in line with our updated operating strategy to reduce the Senior distribution business and focus resources on Healthcare Services. Total approved policies decreased by 21% for the six months ended December 31, 2022, compared to the six months ended December 31, 2021. Fluctuations in approved policies are normally in direct correlation to submitted policies; however, due to our increased focus on agent training and development and a higher mix of tenured agents, we experienced a 10% and a 9% improvement

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

in the submitted-to-approved conversion rates for the three and six months ended December 31, 2022, compared to the three and six months ended December 31, 2021.

***Lifetime Value of Commissions per Approved Policy***

The lifetime value of commissions (the "LTV") per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix, and expected policy persistency with applied constraints. The LTV per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions. The estimate of the future renewal commissions is determined using contracted renewal commission rates constrained by a persistency-adjusted 10-year renewal period based on a combination of our historical experience and available insurance carrier historical experience to estimate renewal revenue only to the extent probable that a material reversal in revenue would not be expected to occur. These factors may result in varying values from period to period. The LTV per approved policy represents commissions only from policies sold during the period; it does not include any updated estimates of prior period variable consideration based on actual policy renewals in the current period.

The following table shows the LTV per approved policy for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Medicare Advantage | $870 | $922 | $845 | $936 |
| Medicare Supplement | 994 | 1347 | 1037 | 1384 |
| Dental, Vision and Hearing | 116 | 112 | 97 | 125 |
| Prescription Drug Plan | 212 | 218 | 219 | 237 |
| Other | 115 | 9 | 91 | 64 |

---

The LTV per MA approved policy decreased 6% for the three months ended December 31, 2022, compared to the three months ended December 31, 2021. The MA LTV was negatively impacted primarily by carrier mix, somewhat offset by higher commission rates.

The LTV per MA approved policy decreased 10% for the six months ended December 31, 2022, compared to the six months ended December 31, 2021. The MA LTV was negatively impacted by carrier mix and lower persistency rates, which includes an increase in constraint and higher provision for renewal year lapse rates, somewhat offset by higher commission rates.

**Healthcare Services**

The total number of SelectRx members represents the amount of active customers to which an order has been shipped, as this is the primary key driver of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

---

| | | |
|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2021** |
| Total SelectRx Members | 39308 | 7693 |

---

The total number of SelectRx members increased by 411% as of December 31, 2022, compared to December 31, 2021, due to the strategic growth of Healthcare Services.

**Combined Senior and Healthcare Services - Consumer Per Unit Economics**

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers has created a need for us to review our key metrics related to our per unit economics. As we think about the revenue and expenses for Healthcare Services, we note that they are derived from the marketing acquisition costs associated with the sale of an MA or MS policy, some of which costs are allocated directly to Healthcare Services, and therefore determined that our per unit economics measure should include components from both Senior and Healthcare Services. See details of revenue and expense items included in the calculation below.

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue per MA/MS policy as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

---

| | | |
|:---|:---|:---|
| | **Twelve Months Ended December 31,** | **Twelve Months Ended December 31,** |
| *(dollars per approved policy):* | **2022** | **2021** |
| Medicare Advantage and Medicare Supplement approved policies | 617687 | 574682 |
| Medicare Advantage and Medicare Supplement commission per MA/MS policy | $880 | $1067 |
| Other commission per MA/MS policy | 19 | 33 |
| Pharmacy revenue per MA/MS policy | 225 | 26 |
| Other revenue per MA/MS policy | 62 | (73) |
| Total revenue per MA/MS policy | 1186 | 1053 |
| Total operating expenses per MA/MS policy | (1111) | (1195) |
| Adjusted EBITDA per MA/MS policy <sup>(1)</sup> | $75 | $(142) |
| Adjusted EBITDA Margin per MA/MS policy <sup>(1)</sup> | 6% | (13)% |
| Revenue/CAC multiple | 3.0X | 1.8X |

---

(1) These financial measures are not calculated in accordance with GAAP. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures" for information regarding our use of these non-GAAP financial measures and a reconciliation of such measures to their nearest comparable financial measures calculated and presented in accordance with GAAP.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

Total revenue per MA/MS policy increased 13% for the twelve months ended December 31, 2022, compared to the twelve months ended December 31, 2021, due to the increase in pharmacy revenue and the downward Senior revenue adjustments from a change in estimate of MA cohort transaction prices that were made during the three months ended December 31, 2021. Total cost per policy decreased 7% for the twelve months ended December 31, 2022, compared to the twelve months ended December 31, 2021, driven by a decrease in our marketing and advertising costs, partially offset by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

**Life**

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for Life.

The following table shows term and final expense premiums for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands):* | **2022** | **2021** | **2022** | **2021** |
| Term Premiums | $15824 | $15548 | $30922 | $31057 |
| Final Expense Premiums | 17093 | 21134 | 39457 | 55186 |
| **Total** | $32917 | $36682 | $70379 | $86243 |

---

Total term premiums remained flat for the three months ended December 31, 2022, compared to the three months ended December 31, 2021, due to the 14% increase in the average premium per policy sold, somewhat offset by the 11% decrease in the number of policies sold which was driven by a lower average agent headcount. Final expense premiums decreased 19% for the three months ended December 31, 2022, compared to the three months ended December 31, 2021. The number of policies sold declined 28% driven by a lower average agent headcount, which was somewhat offset by a 13% increase in the average premium per policy sold.

Total term premiums remained flat for the six months ended December 31, 2022, compared to the six months ended December 31, 2021, due to the 12% increase in the average premium per policy sold, somewhat offset by the 11% decrease in the number of policies sold which was driven by a lower average agent headcount. Final expense premiums decreased 29% for the six months ended December 31, 2022, compared to the six months ended December 31, 2021. The number of policies sold declined 37% driven by a lower average agent headcount, which was somewhat offset by a 13% increase in the average premium per policy sold.

**Auto & Home**

Auto & Home premium represents the total premium value of all new policies that were approved by our insurance carrier partners during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for Auto & Home.

The following table shows premiums for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands):* | **2022** | **2021** | **2022** | **2021** |
| Premiums | $12080 | $10585 | $23628 | $23843 |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

Total premiums increased 14% for the three months ended December 31, 2022, compared to the three months ended December 31, 2021, driven by a 8% increase in the number of policies sold and a 6% increase in the average premium per policy sold.

Total premiums remained flat for the six months ended December 31, 2022, compared to the six months ended December 31, 2021. The number of policies sold decreased 8%, which was offset by an 8% increase in the average premium per policy sold.

**Non-GAAP Financial Measures**

To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this Quarterly Report on Form 10-Q Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies.

*Adjusted EBITDA.* We define Adjusted EBITDA as income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for transaction costs and non-cash or non-recurring expenses, including restructuring, share-based compensation expenses, and any impairment charges. The most directly comparable GAAP measure is net income (loss). We monitor and have presented in this Quarterly Report on Form 10-Q Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets, and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

We believe that this non-GAAP financial measure helps identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of this non-GAAP financial measure. Accordingly, we believe that this financial measure provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.

Adjusted EBITDA is not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of this non-GAAP financial measure rather than net income (loss), which is the most directly comparable financial measure calculated and presented in accordance with GAAP. These limitations include the fact that Adjusted EBITDA excludes interest expense, depreciation and amortization expense, share-based compensation expense, income tax expense (benefit), and other non-recurring expenses that are one-time in nature. In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

The following tables reconcile Adjusted EBITDA and net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the periods presented:

**Three Months Ended December 31, 2022**:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** | **Consolidated** |
| Net income |  |  |  |  |  | $22514 |
| &nbsp;&nbsp;Share-based compensation expense |  |  |  |  |  | 2936 |
| &nbsp;&nbsp;Transaction costs <sup>(1)</sup> |  |  |  |  |  | 442 |
| &nbsp;&nbsp;Depreciation and amortization |  |  |  |  |  | 7188 |
| &nbsp;&nbsp;Loss on disposal of property, equipment, and software |  |  |  |  |  | 46 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  |  | 21044 |
| &nbsp;&nbsp;Income tax expense |  |  |  |  |  | 9405 |
| **Adjusted EBITDA** | $83617 | $(9301) | $5843 | $2284 | $(18868) | $63575 |

---

(1) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility and non-restructuring severance expenses.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Three Months Ended December 31, 2021:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** | **Consolidated** |
| Net loss |  |  |  |  |  | $(137563) |
| &nbsp;&nbsp;Share-based compensation expense |  |  |  |  |  | 1894 |
| &nbsp;&nbsp;Non-recurring expenses <sup>(1)</sup> |  |  |  |  |  | 1602 |
| &nbsp;&nbsp;Depreciation and amortization |  |  |  |  |  | 6175 |
| &nbsp;&nbsp;Loss on disposal of property, equipment, and software |  |  |  |  |  | 5 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  |  | 10587 |
| &nbsp;&nbsp;Income tax benefit |  |  |  |  |  | (46725) |
| **Adjusted EBITDA** | $(140220) | $(8415) | $1106 | $1435 | $(17931) | $(164025) |

---

(1) These expenses primarily consist of debt issuance costs incurred for the Second Amendment.

**Six Months Ended December 31, 2022**:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** | **Consolidated** |
| **Net loss** |  |  |  |  |  | $(19970) |
| &nbsp;&nbsp;Share-based compensation expense |  |  |  |  |  | 5566 |
| &nbsp;&nbsp;Transaction costs<sup>(1)</sup> |  |  |  |  |  | 2570 |
| &nbsp;&nbsp;Depreciation and amortization |  |  |  |  |  | 13990 |
| &nbsp;&nbsp;Loss on disposal of property, equipment, and software |  |  |  |  |  | 371 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  |  | 37780 |
| &nbsp;&nbsp;Income tax benefit |  |  |  |  |  | (4205) |
| **Adjusted EBITDA** | $79766 | $(21089) | $11068 | $4725 | $(38368) | $36102 |

---

(1) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Six Months Ended December 31, 2021:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** | **Consolidated** |
| Net loss |  |  |  |  |  | $(185795) |
| &nbsp;&nbsp;Share-based compensation expense |  |  |  |  |  | 4109 |
| &nbsp;&nbsp;Non-recurring expenses<sup>(1)</sup> |  |  |  |  |  | 2155 |
| &nbsp;&nbsp;Depreciation and amortization |  |  |  |  |  | 11278 |
| &nbsp;&nbsp;Loss on disposal of property, equipment, and software |  |  |  |  |  | 355 |
| &nbsp;&nbsp;Interest expense, net |  |  |  |  |  | 19122 |
| &nbsp;&nbsp;Income tax benefit |  |  |  |  |  | (63138) |
| **Adjusted EBITDA** | $(169261) | $(12345) | $1961 | $2808 | $(35077) | $(211914) |

---

(1) These expenses primarily consist of costs incurred for the Second Amendment and costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Key Components of our Results of Operations**

The following table sets forth our operating results and related percentage of total revenues for the periods presented:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2022** | **2021** | **2021** | **2022** | **2022** | **2021** | **2021** |
| Revenue |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission | $230033 | 72% | $139957 | 72% | $336368 | 70% | $270764 | 77% |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharmacy | 51601 | 16% | 8770 | 5% | 92694 | 19% | 13237 | 4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 37554 | 12% | 45510 | 23% | 52610 | 11% | 66315 | 19% |
| Total revenue | 319188 | 100% | 194237 | 100% | 481672 | 100% | 350316 | 100% |
| Operating costs and expenses |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of revenue | 91477 | 29% | 136189 | 70% | 156641 | 33% | 222980 | 64% |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold—pharmacy revenue | 50096 | 16% | 10172 | 5% | 92450 | 19% | 15043 | 4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketing and advertising | 89925 | 28% | 193246 | 99% | 147519 | 31% | 283923 | 81% |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 28412 | 9% | 21894 | 11% | 59118 | 12% | 45789 | 13% |
| &nbsp;&nbsp;&nbsp;&nbsp;Technical development | 6245 | 2% | 6386 | 3% | 12427 | 3% | 12239 | 3% |
| Total operating costs and expenses | 266155 | 84% | 367887 | 188% | 468155 | 98% | 579974 | 165% |
| Income (loss) from operations | 53033 | 17% | (173650) | (89)% | 13517 | 3% | (229658) | (66)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | (21044) | (7)% | (10587) | (5)% | (37780) | (8)% | (19122) | (5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | (70) | —% | (51) | —% | 88 | —% | (153) | —% |
| Income (loss) before income tax expense (benefit) | 31919 | 10% | (184288) | (94)% | (24175) | (5)% | (248933) | (71)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 9405 | 3% | (46725) | (24)% | (4205) | (1)% | (63138) | (18)% |
| **Net income (loss)** | $22514 | 7% | $(137563) | (70)% | $(19970) | (4)% | $(185795) | (53)% |

---

***Revenue***

We earn revenue in the form of commission payments from our insurance carrier customers, for the initial year the policy is in effect ("first year") and, where applicable, for each subsequent year the policy renews ("renewal year"), as presented in our condensed consolidated statements of comprehensive income as commission revenue. We also receive certain volume-based bonuses from some carriers on first year policies sold based on attaining various predetermined target sales levels or other agreed upon objectives. These bonuses are referred to as "production bonuses" or "marketing development funds" and are included in other revenue in the condensed consolidated statements of comprehensive income. Pharmacy revenue includes revenue from the sale of prescription and OTC medications from SelectRx. Other revenue includes production bonuses and marketing development funds noted above, revenue from Population Health for performing HRAs and making transfers or appointments with VBC partners, and external lead generation revenue from InsideResponse.

Our commission contracts with our insurance carrier partners contain a single performance obligation satisfied at the point in time to which we allocate the total transaction price. The transaction price is identified as the first year commission due upon the initial sale of a policy as well as an estimate of future renewal commissions and production bonus revenue when applicable. After a policy is sold, we have no material additional or recurring obligations to the policyholder or the insurance carrier partner. Therefore, we do not incur any additional expense related to our receipt of future renewal commissions or production bonus revenue. All of the costs associated with

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

the sale of an individual policy are incurred prior to or at the time of the initial sale of an individual policy. Revenue is recognized at different milestones for Senior, Life, and Auto & Home and is based on the contractual enforceable rights, our historical experience, and established customer business practices. Lead generation revenue is recognized when the generated lead is accepted by our customers, which is the point of sale, and we have no performance obligation after the delivery. Revenues generated from SelectRx are recognized upon shipment. At the time of shipment, we have performed substantially all of our performance obligations and do not experience a significant level of returns or re-shipments. There are no future revenue streams associated as patients have the option to cancel their service at any time with no further payments due. Revenue from Population Health is recognized when the HRA has been performed or the agreed-upon task has been completed for a VBC partner, the transaction price is known based on volume and contractual prices, and we have no further performance obligation.

The following table presents our revenue for the periods presented and the percentage changes from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Commission | $230033 | $139957 | 64% | $336368 | $270764 | 24% |
| Pharmacy | 51601 | 8770 | 488% | 92694 | 13237 | 600% |
| Other | 37554 | 45510 | (17)% | 52610 | 66315 | (21)% |
| **Total revenue** | $319188 | $194237 | 64% | $481672 | $350316 | 38% |

---

**Three Months Ended December 31, 2022 and 2021–**Commission revenue increased $90.1 million, or 64%, for the three months ended December 31, 2022, and included increases in Senior, Life, and Auto & Home commission revenue of $84.2 million, $3.2 million, and $1.7 million respectively. For Senior, excluding the $145.0 million cohort adjustment recorded during the three months ended December 31, 2021, revenue decreased $60.8 million during the three months ended December 31, 2022, which was driven by a 24% decrease in approved policies and a 1% reduction in LTV's, partially offset by higher commission rates. Life's revenue increase was primarily driven by a $3.0 million increase in final expense revenue. The $42.8 million increase in pharmacy revenue was due to the increase in members from December 31, 2021, and the expansion of the SelectRx business. The $8.0 million decrease in other revenue was primarily driven by a $4.6 million decrease in external lead generation revenue and a $5.0 million decrease in production bonus revenue, offset by an increase in Population Health revenue of $1.6 million.

**Six Months Ended December 31, 2022 and 2021–**Commission revenue increased $65.6 million, or 24%, for the six months ended December 31, 2022, and included increases in Senior and Auto & Home commission revenue of $65.4 million and $1.4 million, respectively, offset by a decrease in Life commission revenue of $3.4 million. For Senior, excluding the $145.0 million cohort adjustment recorded during the six months ended December 31, 2021, commission revenue decreased $79.6 million during the six months ended December 31, 2022, which was driven by a 21% decrease in approved policies and a 3% reduction in LTV's, partially offset by higher commission rates. Life's revenue decline was primarily driven by a $2.7 million decrease in final expense revenue. The $79.5 million increase in pharmacy revenue was due to the increase in members from December 31, 2021, and the expansion of the SelectRx business. The $13.7 million decrease in other revenue was primarily driven by an $8.7 million decrease in external lead generation revenue and a $7.0 million decrease in production bonus revenue, offset by an increase in Population Health revenue of $2.0 million.

**Operating Costs and Expenses**

***Cost of Revenue***

Cost of revenue represents the direct costs associated with fulfilling our obligations to our customers in the Senior, Life, Auto & Home, and Population Health divisions, primarily compensation, benefits, and licensing for

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

sales agents, customer success agents, fulfillment specialists, and others directly engaged in serving customers. It also includes allocations for facilities, telecommunications, and software maintenance costs, which are all based on headcount. Facilities costs include rent and utilities expenses and other costs to maintain our office locations. Telecommunications and software maintenance costs includes costs related to the internal phone systems and various software applications that our agents use to make sales. These costs directly correlate to the number of agents we have as we are primarily charged based on per person usage for the phone systems and software applications.

The following table presents our cost of revenue for the periods presented and the percentage change from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Cost of revenue | $91477 | $136189 | (33)% | $156641 | $222980 | (30)% |

---

**Three Months Ended December 31, 2022 and 2021–**Cost of revenue decreased $44.7 million, or 33%, for the three months ended December 31, 2022, primarily due to a $32.3 million decrease in compensation costs, a $6.0 million decrease in licensing costs, and $6.4 million decrease in allocations for facilities, telecommunications, and software maintenance costs, all of which is due to the reduction in our agent headcount.

**Six Months Ended December 31, 2022 and 2021–**Cost of revenue decreased $66.3 million, or 30%, for the six months ended December 31, 2022, primarily due to a $48.1 million decrease in compensation costs, a $10.6 million decrease in licensing costs, and a $7.9 million decrease in allocations for facilities, telecommunications, and software maintenance costs, all of which is due to the reduction in our agent headcount.

***Cost of Goods Sold-Pharmacy Revenue***

Cost of goods sold-pharmacy revenue represents the direct costs associated with fulfilling pharmacy patient orders for SelectRx. Such costs primarily consist of medication costs and compensation and related benefit costs for licensed pharmacists, pharmacy technicians, and other employees directly associated with fulfilling orders such as packaging and shipping clerks. It also includes shipping, supplies, other order fulfillment costs including part of the one-time customer onboarding costs, and certain facilities overhead costs such as rent, maintenance, and depreciation related to the pharmacy production process.

The following table presents our cost of goods sold-pharmacy revenue for the periods presented and the percentage change from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Cost of goods sold—pharmacy revenue | $50096 | $10172 | 392% | $92450 | $15043 | 515% |

---

**Three Months Ended December 31, 2022 and 2021–**Cost of goods sold-pharmacy revenue increased $39.9 million, or 392%, for the three months ended December 31, 2022, due to a $32.3 million increase in medication costs, a $1.5 million increase in shipping and fulfillment costs, and a $4.8 million increase in compensation costs as the number of SelectRx members increased 411% over the prior year.

**Six Months Ended December 31, 2022 and 2021–**Cost of goods sold-pharmacy revenue increased $77.4 million, or 515%, for the six months ended December 31, 2022, due to a $59.4 million increase in medication costs,

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

a $3.7 million increase in shipping and fulfillment costs, and an $11.8 million increase in compensation costs as the number of SelectRx members increased 411% over the prior year.

***Marketing and Advertising***

Marketing and advertising expenses consist primarily of the direct costs associated with marketing and advertising of our services, such as television and radio commercials and online advertising. These direct costs generally represent the vast majority of our marketing and advertising expenses. Other costs consist of compensation and other expenses related to marketing, business development, partner management, public relations, carrier relations personnel who support our offerings, and allocations for facilities, telecommunications, and software maintenance costs. Our marketing and advertising costs increase during AEP and OEP to generate more leads during these high-volume periods.

The following table presents our marketing and advertising expenses for the periods presented and the percentage change from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Marketing and advertising | $89925 | $193246 | (53)% | $147519 | $283923 | (48)% |

---

**Three Months Ended December 31, 2022 and 2021–**Marketing and advertising expenses decreased $103.3 million, or 53%, for the three months ended December 31, 2022, due to a $96.0 million decrease in lead costs due to the decrease in volume associated with the Company's updated operating strategy, as well as a $7.1 million decrease in compensation costs. However, we've seen an increase in marketing efficiency as our CAC per approved policy has decreased due to improved agent close rates as a result of increased focus on agent training and development.

**Six Months Ended December 31, 2022 and 2021–**Marketing and advertising expenses decreased $136.4 million, or 48%, for the six months ended December 31, 2022, due to a $129.1 million decrease in lead costs due to the decrease in volume associated with the Company's updated operating strategy, as well as a $7.6 million decrease in compensation and benefits. However, we've seen an increase in marketing efficiency as our CAC per approved policy has decreased due to improved agent close rates as a result of increased focus on agent training and development.

***Selling, General, and Administrative***

Selling, general, and administrative expenses include compensation and benefits costs for staff working in our executive, finance, accounting, recruiting, human resources, administrative, business intelligence, data science, and part of the SelectRx customer onboarding departments. These expenses also include fees paid for outside professional services, including audit, tax and legal fees and allocations for facilities, telecommunications, and software maintenance costs.

The following table presents our selling, general, and administrative expenses for the periods presented and the percentage change from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Selling, general, and administrative | $28412 | $21894 | 30% | $59118 | $45789 | 29% |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Three Months Ended December 31, 2022 and 2021–**Selling, general, and administrative expenses increased $6.5 million, or 30%, for the three months ended December 31, 2022, primarily due to a $6.7 million increase in compensation costs, mostly related to the expansion of SelectRx.

**Six Months Ended December 31, 2022 and 2021–**Selling, general, and administrative expenses increased $13.3 million, or 29%, for the six months ended December 31, 2022, primarily due to $11.9 million increase in compensation costs, mostly related to the expansion of SelectRx.

***Technical Development***

Technical development expenses consist primarily of compensation and benefits costs for internal and external personnel associated with developing, maintaining, and enhancing our applications, infrastructure and other IT-related functions as well as allocations for facilities, telecommunications and software maintenance costs.

The following table presents our technical development expenses for the periods presented and the percentage change from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Technical development | $6245 | $6386 | (2)% | $12427 | $12239 | 2% |

---

**Three and Six Months Ended December 31, 2022 and 2021–**Technical development expenses remained flat for the three and six months ended December 31, 2022.

***Interest Expense, Net***

The following table presents our interest expense, net for the periods presented and the percentage changes from the prior year:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2021 vs. 2020** |
| Interest expense, net | $(21044) | $(10587) | 99% | $(37780) | $(19122) | 98% |

---

**Three Months Ended December 31, 2022 and 2021–**Interest expense increased $10.5 million, or 99%, for the three months ended December 31, 2022, primarily as a result of interest incurred on the Term Loans due to additional principal outstanding and changes under the Fourth Amendment, as well as the amortization of additional deferred financing costs associated with the amendments to the Senior Secured Credit Facility, all of which was partially offset by interest income received from the interest rate swap and on our money market account.

**Six Months Ended December 31, 2022 and 2021–**Interest expense increased $18.7 million, or 98%, for the six months ended December 31, 2022, primarily as a result of interest incurred on the Term Loans due to additional principal outstanding and changes under the Fourth Amendment, as well as the amortization and write-off of additional deferred financing costs associated with the amendments to the Senior Secured Credit Facility, all of which was partially offset by interest income received from the interest rate swap and on our money market account.

***Income Taxes***

The following table presents our provision for income taxes for the periods presented and the percentage change from the prior year:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Percent Change** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Percent Change** |
| *(dollars in thousands)* | **2022** | **2021** | **2022 vs. 2021** | **2022** | **2021** | **2022 vs. 2021** |
| Income tax expense (benefit) | $9405 | $(46725) | (120)% | $(4205) | $(63138) | (93)% |
| Effective tax rate | 29.5% | 25.4% |  | 17.4% | 25.4% |  |

---

**Three Months Ended December 31, 2022 and 2021–**For the three months ended December 31, 2022 and 2021, we recognized income tax expense (benefit) of $9.4 million and $(46.7) million, respectively, representing effective tax rates of 29.5% and 25.4%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2022, were primarily related to state income taxes, RSU vestings, and the recording of a valuation allowance for state tax attributes that the Company does not expect to utilize prior to expiration. The differences from our federal statutory tax rate to the effective tax rate for the three months ended December 31, 2021, were primarily related to state income taxes.

**Six Months Ended December 31, 2022 and 2021–**For the six months ended December 31, 2022 and 2021, we recognized income tax benefits of $4.2 million and $63.1 million, respectively, representing effective tax rates of 17.4% and 25.4%, respectively. The differences from our federal statutory tax rate to the effective tax rate for the six months ended December 31, 2022, were primarily related to state income taxes, RSU vestings, and the recording of a valuation allowance for state tax attributes that the Company does not expect to utilize prior to expiration. The differences from our federal statutory tax rate to the effective tax rate for the six months ended December 31, 2021, were primarily related to state income taxes.

**Segment Information**

Prior to the first quarter of fiscal 2023, we reported financial results under three reportable segments: i) Senior, ii) Life, and iii) Auto & Home. Effective July 1, 2022, we realigned our reportable segments as a result of the change in strategic direction established for fiscal year 2023. This realignment separated the Healthcare Services business, which includes SelectRx and Population Health, out of the Senior reportable segment and into its own operating and reportable segment. Our chief operating decision maker ("CODM") reviews discrete financial information for Healthcare Services, separate from Senior, to make operational and financial decisions and allocate resources, consistent with this realignment. As a result, the Company now reflects four reportable segments: i) Senior, ii) Healthcare Services, iii) Life, and iv) Auto & Home, and all prior periods have been restated to reflect the new presentation. In addition, we account for non-operating activity, share-based compensation expense, certain intersegment eliminations, and the costs of providing corporate and other administrative services in our administrative division, Corporate & Eliminations. These services are not directly identifiable with our reportable segments and are shown in the tables below to reconcile the reportable segments to the condensed consolidated financial statements. We have not aggregated any operating segments together to represent a reportable segment.

Costs of revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, cost of goods sold, marketing and advertising, technical development, and selling, general, and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; and non-recurring expenses such as severance payments and transaction costs. Our CODM does not separately evaluate assets by segment; therefore, assets by segment are not presented.

The following tables present information about the reportable segments for the periods presented:

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Three Months Ended December 31, 2022:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $223826 | $55480 | $33995 | $7808 | $(1921) | (1) | $319188 |
| Operating expenses | (140209) | (64781) | (28152) | (5524) | (16877) | (2) | (255543) |
| Other income (expense), net |  |  |  |  | (70) |  | (70) |
| **Adjusted EBITDA** | $83617 | $(9301) | $5843 | $2284 | $(18868) |  | 63575 |
| Share-based compensation expense |  |  |  |  |  |  | (2936) |
| Transaction costs<sup>(3)</sup> |  |  |  |  |  |  | (442) |
| Depreciation and amortization |  |  |  |  |  |  | (7188) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (46) |
| Interest expense, net |  |  |  |  |  |  | (21044) |
| Income tax expense |  |  |  |  |  |  | (9405) |
| **Net income** |  |  |  |  |  |  | $22514 |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $12.2 million in salaries and benefits for certain general, administrative, and IT related departments and $4.6 million in professional services fees.

(3) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility and non-restructuring severance expenses.

**Three Months Ended December 31, 2021:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $147694 | $11077 | $32036 | $6135 | $(2705) | (1) | $194237 |
| Operating expenses | (287914) | (19492) | (30930) | (4700) | (15175) | (2) | (358211) |
| Other expenses, net |  |  |  |  | (51) |  | (51) |
| **Adjusted EBITDA** | $(140220) | $(8415) | $1106 | $1435 | $(17931) |  | (164025) |
| Share-based compensation expense |  |  |  |  |  |  | (1894) |
| Non-recurring expenses <sup>(3)</sup> |  |  |  |  |  |  | (1602) |
| Depreciation and amortization |  |  |  |  |  |  | (6175) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (5) |
| Interest expense, net |  |  |  |  |  |  | (10587) |
| Income tax benefit |  |  |  |  |  |  | 46725 |
| **Net loss** |  |  |  |  |  |  | $(137563) |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments primarily for referrals from Senior to the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $11.2 million in salaries and benefits for certain general, administrative, and IT related departments and $4.3 million in professional services fees.

(3) These expenses primarily consist of debt issuance costs incurred for the Second Amendment.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Six Months Ended December 31, 2022:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $301340 | $98546 | $70830 | $14890 | $(3934) | (1) | $481672 |
| Operating expenses | (221574) | (119635) | (59963) | (10164) | (34322) | (2) | (445658) |
| Other income (expense), net |  |  | 201 | (1) | (112) |  | 88 |
| **Adjusted EBITDA** | $79766 | $(21089) | $11068 | $4725 | $(38368) |  | 36102 |
| Share-based compensation expense |  |  |  |  |  |  | (5566) |
| Transaction costs<sup>(3)</sup> |  |  |  |  |  |  | (2570) |
| Depreciation and amortization |  |  |  |  |  |  | (13990) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (371) |
| Interest expense, net |  |  |  |  |  |  | (37780) |
| Income tax benefit |  |  |  |  |  |  | 4205 |
| **Net loss** |  |  |  |  |  |  | $(19970) |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments, including for lead generation referrals from InsideResponse (within Senior) and referrals between the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $24.3 million in salaries and benefits for certain general, administrative, and IT related departments and $9.2 million in professional services fees.

(3) These expenses primarily consist of costs related to the Fourth Amendment to the Senior Secured Credit Facility.

**Six Months Ended December 31, 2021:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *(in thousands)* | **Senior** | **Healthcare Services** | **Life** | **Auto & Home** | **Corp & Elims** |  | **Consolidated** |
| Revenue | $248299 | $17060 | $78019 | $13604 | $(6666) | (1) | $350316 |
| Operating expenses | (417560) | (29405) | (76058) | (10796) | (28258) | (2) | (562077) |
| Other expenses, net |  |  |  |  | (153) |  | (153) |
| **Adjusted EBITDA** | $(169261) | $(12345) | $1961 | $2808 | $(35077) |  | (211914) |
| Share-based compensation expense |  |  |  |  |  |  | (4109) |
| Non-recurring expenses <sup>(3)</sup> |  |  |  |  |  |  | (2155) |
| Depreciation and amortization |  |  |  |  |  |  | (11278) |
| Loss on disposal of property, equipment, and software |  |  |  |  |  |  | (355) |
| Interest expense, net |  |  |  |  |  |  | (19122) |
| Income tax benefit |  |  |  |  |  |  | 63138 |
| **Net loss** |  |  |  |  |  |  | $(185795) |

---

(1) Revenue in the Corp & Elims division represents intercompany revenue eliminated between segments primarily for lead generation referrals from InsideResponse (within Senior) to the other segments.

(2) Operating expenses in the Corp & Elims division primarily include $21.6 million in salaries and benefits for certain general, administrative, and IT related departments and $9.0 million in professional services fees.

(3) These expenses primarily consist of costs incurred for the Second Amendment and costs related to the acquisitions of Express Med Pharmaceuticals and Simple Meds.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

The following table depicts the disaggregation of revenue by segment and product for the periods presented:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(dollars in thousands)* | **2022** | **2021** | $**%** | **2022** | **2021** | $**%** |
| **Senior:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare advantage | $190479 | $99262 | 92% | $256836 | $179345 | 43% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare supplement | 1056 | 2332 | (55)% | 1171 | 3936 | (70)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prescription drug plan | 187 | 732 | (74)% | 278 | 1001 | (72)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dental, vision, and health | 1682 | 4920 | (66)% | 2018 | 8136 | (75)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other commission revenue | 779 | 2758 | (72)% | 1435 | 3926 | (63)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 194183 | 110004 | 77% | 261738 | 196344 | 33% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 29643 | 37690 | (21)% | 39602 | 51955 | (24)% |
| **Total Senior revenue** | 223826 | 147694 | 52% | 301340 | 248299 | 21% |
| **Healthcare Services:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total pharmacy revenue | 51601 | 8770 | 488% | 92694 | 13237 | 600% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 3879 | 2307 | 68% | 5852 | 3823 | 53% |
| **Total Healthcare Services revenue** | 55480 | 11077 | 401% | 98546 | 17060 | 478% |
| **Life:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commission revenue: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term | 16317 | 16126 | 1% | 31693 | 32372 | (2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Final expense | 13134 | 10142 | 30% | 30553 | 33281 | (8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 29451 | 26268 | 12% | 62246 | 65653 | (5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 4544 | 5768 | (21)% | 8584 | 12366 | (31)% |
| **Total Life revenue** | 33995 | 32036 | 6% | 70830 | 78019 | (9)% |
| **Auto & Home:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 7364 | 5657 | 30% | 14045 | 12649 | 11% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 444 | 478 | (7)% | 845 | 955 | (12)% |
| **Total Auto & Home revenue** | 7808 | 6135 | 27% | 14890 | 13604 | 9% |
| **Eliminations:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | (965) | (1972) | (51)% | (1661) | (3882) | (57)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | (956) | (733) | 30% | (2273) | (2784) | (18)% |
| **Total Elimination revenue** | (1921) | (2705) | (29)% | (3934) | (6666) | (41)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total commission revenue | 230033 | 139957 | 64% | 336368 | 270764 | 24% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total pharmacy revenue | 51601 | 8770 | 488% | 92694 | 13237 | 600% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other revenue | 37554 | 45510 | (17)% | 52610 | 66315 | (21)% |
| **Total revenue** | $319188 | $194237 | 64% | $481672 | $350316 | 38% |

---

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

***Revenue by Segment***

**Three Months Ended December 31, 2022 and 2021–**Revenue from Senior was $223.8 million for the three months ended December 31, 2022, a $76.1 million, or 52%, increase compared to revenue of $147.7 million for the three months ended December 31, 2021. The increase was due to an $84.2 million, or 77%, increase in commission revenue, partially offset by $4.3 million and $3.7 million decreases in lead generation and marketing development funds revenue earned, respectively.

Revenue from Healthcare Services was $55.5 million for the three months ended December 31, 2022, a $44.4 million, or 401%, increase compared to revenue of $11.1 million for the three months ended December 31, 2021, primarily due to a $42.8 million increase in SelectRx pharmacy revenue.

Revenue from Life was $34.0 million for the three months ended December 31, 2022, a $2.0 million, or 6%, increase compared to revenue of $32.0 million for the three months ended December 31, 2021, in line with our updated operating strategy to stabilize our distribution business.

Revenue from Auto & Home was $7.8 million for the three months ended December 31, 2022, a $1.7 million, or 27%, increase compared to revenue of $6.1 million for the three months ended December 31, 2021, in line with our updated operating strategy to stabilize our distribution business.

**Six Months Ended December 31, 2022 and 2021–**Revenue from Senior was $301.3 million for the six months ended December 31, 2022, a $53.0 million, or 21%, increase compared to revenue of $248.3 million for the six months ended December 31, 2022. The increase was due to a $65.4 million, or 33%, increase in commission revenue, partially offset by a $9.2 million and $3.1 million decrease in lead generation revenue and marketing development funds received, respectively.

Revenue from Healthcare Services was $98.5 million for the six months ended December 31, 2022, a $81.5 million, or 478%, increase compared to revenue of $17.1 million for the six months ended December 31, 2021, primarily due to a $79.5 million increase in SelectRx pharmacy revenue.

Revenue from Life was $70.8 million for the six months ended December 31, 2022, a $7.2 million, or 9%, decrease compared to revenue of $78.0 million for the six months ended December 31, 2022, in line with our updated operating strategy to stabilize our distribution business.

Revenue from Auto & Home was $14.9 million for the six months ended December 31, 2022, a $1.3 million, or 9%, increase compared to revenue of $13.6 million for the six months ended December 31, 2022, in line with our updated operating strategy to stabilize our distribution business.

***Adjusted EBITDA by Segment***

**Three Months Ended December 31, 2022 and 2021–**Adjusted EBITDA from Senior was $83.6 million for the three months ended December 31, 2022, a $223.8 million increase compared to Adjusted EBITDA of $(140.2) million for the three months ended December 31, 2021. The increase was due to a $76.1 million increase in revenue and a $147.7 million decrease in operating costs and expenses, primarily due to a $94.5 million reduction in marketing and advertising costs, a $39.9 million reduction in compensation costs, and a $5.5 million reduction in licensing fees, all of which support our updated operating strategy.

Adjusted EBITDA from Healthcare Services was $(9.3) million for the three months ended December 31, 2022, a $0.9 million decrease compared to Adjusted EBITDA of $(8.4) million for the three months ended December 31, 2021. The decrease was due to a $45.3 million increase in operating costs and expenses primarily as a result of the $32.3 million increase in medication costs and a $9.7 million increase in compensation costs in support of the growth of Healthcare Services. The increase in operating costs and expenses was offset by the $44.4 million increase in revenue as discussed above.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

Adjusted EBITDA from Life was $5.8 million for the three months ended December 31, 2022, a $4.7 million increase compared to Adjusted EBITDA of $1.1 million for the three months ended December 31, 2021. The increase was due to a $2.0 million increase in revenue and a $2.8 million decrease in operating costs and expenses primarily due to a $2.6 million reduction in marketing and advertising costs, which support our updated operating strategy.

Adjusted EBITDA from Auto & Home was $2.3 million for the three months ended December 31, 2022, a $0.8 million, or 59%, increase compared to Adjusted EBITDA of $1.4 million for the three months ended December 31, 2021. The increase was due to a $1.7 million increase in revenue offset by a $0.8 million increase in operating costs and expenses due to $0.6 million and $0.2 million increase in compensation and fulfillment costs, respectively, all of which support our updated operating strategy.

**Six Months Ended December 31, 2022 and 2021–**Adjusted EBITDA from Senior was $79.8 million for the six months ended December 31, 2022, a $249.0 million increase compared to Adjusted EBITDA of $(169.3) million for the six months ended December 31, 2021. The increase was due to a $196.0 million decrease in operating costs and expenses primarily due to a $118.6 million reduction in marketing and advertising costs, a $57.4 million reduction in compensation costs, and a $9.1 million reduction in licensing fees, all of which support our updated operating strategy.

Adjusted EBITDA from Healthcare Services was $(21.1) million for the six months ended December 31, 2022, a $8.7 million decrease compared to Adjusted EBITDA of $(12.3) million for the six months ended December 31, 2021. The decrease was due to a $90.2 million increase in operating costs and expenses primarily as a result of the $59.4 million increase in medication costs, $24.1 million increase in compensation costs, and $3.7 million increase in fulfillment costs in support of the growth of Healthcare Services. The increase in operating costs and expenses was offset by the $81.5 million increase in revenue as discussed above.

Adjusted EBITDA from Life was $11.1 million for the six months ended December 31, 2022, a $9.1 million increase compared to Adjusted EBITDA of $2.0 million for the six months ended December 31, 2021. The increase was due to a $16.1 million decrease in operating costs and expenses primarily due to a $13.5 million reduction in marketing and advertising costs and a $2.1 million reduction in compensation costs, all of which support our updated operating strategy. The decrease in operating costs and expenses was offset by the $7.2 million decrease in revenue as discussed above.

Adjusted EBITDA from Auto & Home was $4.7 million for the six months ended December 31, 2022, a $1.9 million, or 68%, increase compared to Adjusted EBITDA of $2.8 million for the six months ended December 31, 2021. The increase was due to a $1.3 million increase in revenue and a $0.6 million decrease in operating costs and expenses due to a $0.7 million reduction in marketing and advertising costs and a $0.2 million reduction in compensation costs, partially offset by an increase in fulfillment costs of $0.3 million, all of which support our updated operating strategy.

**Liquidity and Capital Resources**

Our liquidity needs primarily include working capital and debt service requirements. We believe that the cash available under the Senior Secured Credit Facility will be sufficient to meet our projected operating and debt service requirements for at least the next 12 months. To the extent that our current liquidity is insufficient to fund future activities, we may need to raise additional funds. If we raise additional funds by issuing equity securities, the ownership of our existing stockholders will be diluted. The incurrence of additional debt financing would result in debt service obligations, and any future instruments governing such debt could provide for operating and financing covenants that could restrict our operations.

Under the Senior Secured Credit Facility, we are required to maintain certain debt covenants, as discussed further in Note 7 to the condensed consolidated financial statements. As of December 31, 2022, we are in compliance with all of our debt covenants and our financial projections indicate that, based on our current business

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

plan, we will remain in compliance with our debt covenants within one year after the date that the condensed consolidated financial statements are issued.

*Cash Flows*

As of December 31, 2022, and June 30, 2022, our cash and cash equivalents totaled $36.1 million and $141.0 million, respectively. Additionally, the following table presents a summary of our cash flows for the periods presented below:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| *(in thousands)* | **2022** | **2021** |
| Net cash used in operating activities | $(75574) | $(305741) |
| Net cash used in investing activities | (4468) | (31062) |
| Net cash (used in) provided by financing activities | (24858) | 243706 |

---

***Operating Activities***

Net cash used in operating activities primarily consists of net income, adjusted for certain non-cash items including depreciation; amortization of intangible assets and internally developed software; deferred income taxes; share-based compensation expense; impairment charges; and the effect of changes in working capital and other activities.

Collection of commissions receivable depends upon the timing of our receipt of commission payments and associated commission statements from our insurance carrier partners. If we were to experience a delay in receiving a commission payment from an insurance carrier partner within a quarter, our operating cash flows for that quarter could be adversely impacted.

A significant portion of our marketing and advertising expenses is driven by the number of leads required to generate the insurance applications we submit to our insurance carrier partners. Our marketing and advertising costs are expensed and generally paid as incurred and since commission revenue is recognized upon approval of a policy but commission payments are paid to us over time, there are working capital requirements to fund the upfront cost of acquiring new policies. During AEP, we experience an increase in the number of submitted Senior insurance applications and marketing and advertising expenses compared to periods outside of AEP. The timing of AEP affects the positive or negative impacts of our cash flows during each quarter.

***Six Months Ended December 31, 2022***—Net cash used in operating activities was $75.6 million, consisting of net loss of $20.0 million, adjustments for non-cash items of $27.0 million, and cash used in operating assets and liabilities of $82.6 million. Adjustments for non-cash items primarily consisted of $14.0 million of depreciation and amortization, $5.6 million of share-based compensation expense, $4.9 million of accrued interest payable in kind on the Term Loans, $3.9 million of amortization of debt issuance costs and debt discount as a result of amendments to the Senior Secured Credit Facility, and $2.1 million of non-cash lease expense, offset by $4.6 million in deferred income taxes. The cash decrease resulting from changes in net operating assets and liabilities primarily consisted of increases of $114.7 million in commissions receivable, partially offset by increases of $1.0 million in accounts payable and accrued expenses, decreases of $14.0 million in accounts receivable, net, and an $18.0 million increase in other liabilities.

***Six Months Ended December 31, 2021***—Net cash used in operating activities was $305.7 million, consisting of net loss of $185.8 million, adjustments for non-cash items of $42.7 million, and cash used in operating assets and liabilities of $77.2 million. Adjustments for non-cash items primarily consisted of $63.5 million in deferred income taxes, $11.3 million of depreciation and amortization related to additional fixed assets purchases to accommodate our growth in headcount and internally developed software in service, $4.1 million of share-based compensation expense, and $3.0 million of amortization of debt issuance costs and debt discount as a result of amendments to the Senior Secured Credit Facility. The cash decrease resulting from changes in net operating assets

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

and liabilities primarily consisted of increases of $39.9 million in commissions receivable, $41.2 million in accounts receivable, and $5.6 million in other current assets, partially offset by increases of $15.1 million in accounts payable and accrued expenses, all driven by the increased marketing and personnel costs for AEP.

***Investing Activities***

Our investing activities primarily consist of purchases of property, equipment, and software and capitalized salaries related to the development of internal-use software.

***Six Months Ended December 31, 2022***—Net cash used in investing activities of $4.5 million was due to $0.6 million of purchases of property and equipment, primarily to support the growth of SelectRx infrastructure, and $3.9 million in purchases of software and capitalized internal-use software development costs.

***Six Months Ended December 31, 2021***—Net cash used in investing activities of $31.1 million was due to $17.9 million of purchases of property and equipment, primarily to support AEP and the growth of SelectRx infrastructure, $5.2 million in purchases of software and capitalized internal-use software, $6.9 million of net cash paid to acquire Simple Meds, and a $1.0 million non-controlling interest equity investment.

***Financing Activities***

Our financing activities primarily consist of payments of debt and related issuance costs and proceeds and payments related to share-based compensation.

***Six Months Ended December 31, 2022***—Net cash used in financing activities of $24.9 million was primarily due to $10.1 million of debt issuance costs related to the Fourth Amendment to the Senior Secured Credit Facility, $13.4 million of principal payments on the Term Loans, and $2.3 million of holdback remitted as part of the Express Med acquisition, partially offset by $1.1 million in proceeds from common stock options exercised and the employee stock purchase plan.

***Six Months Ended December 31, 2021***—Net cash provided by financing activities of $243.7 million was primarily due to $242.0 million in net proceeds from the DDTL Facility and $2.3 million in proceeds from common stock options exercised and the employee stock purchase plan, partially offset by $0.3 million in debt issuance costs related to the Second Amendment and Third Amendment to the Senior Secured Credit Facility.

***Senior Secured Credit Facility***

We entered into the Senior Secured Credit Facility to provide access to cash, in a variety of methods, when necessary to fund the operations of the business. There were no amounts outstanding under the Revolving Credit Facility as of December 31, 2022. As of December 31, 2022, there was $704.9 million outstanding under the Term Loans. Refer to Note 7 to the condensed consolidated financial statements for further details.

Our risk management strategy includes entering into interest rate swap agreements to protect against unfavorable interest rate changes relating to forecasted debt transactions. The Company's Amended Interest Rate Swap is designated as a cash flow hedge of the interest payments on $325.0 million in principal of the Term Loans. Refer to Note 7 to the condensed consolidated financial statements for further details.

**Contractual Obligations**

Other than the discussions in Note 8 and Note 10 to the condensed consolidated financial statements, as of December 31, 2022, there have been no material changes to our contractual obligations as previously described in our Annual Report.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**Off-Balance Sheet Arrangements**

We did not have any off-balance sheet arrangements during the period covered by this report.

**Recent Accounting Pronouncements**

For a discussion of new accounting pronouncements recently adopted and not yet adopted, see the notes to our condensed consolidated financial statements.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS**

We are primarily exposed to the market risk associated with unfavorable movements in interest rates. The risk inherent in our market risk-sensitive instruments and positions is the potential loss or increased expense arising from adverse changes in those factors. There have been no material changes to our market risk policies or our market risk-sensitive instruments and positions as described in our Annual Report.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Our Disclosure Controls and Procedures**

The Company completed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), carried out by our management, with the participation of our chief executive officer (principal executive officer), chief financial officer (principal financial officer), and chief accounting officer (principal accounting officer). Based upon our management's evaluation, our chief executive officer and our chief financial officer concluded that as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure.

As previously disclosed in our Annual Report, management identified a design deficiency in internal control over financial reporting that resulted in a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The Company obtains and uses relevant information from third party carriers related to final expense policyholder lapses and did not evaluate it on a timely basis to ensure the carrier and policy information utilized to determine the first year commission revenue provision was complete and accurate, which could have resulted in a material misstatement of the Company's consolidated financial statements. The material weakness did contribute to an actual error related to Life first year commission revenue provision for certain final expense policies that was not material to the consolidated financial statements for the year ended June 30, 2021, and for the three months ended September 30, 2021, December 31, 2021, and March 31, 2022.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only a reasonable level of assurance of achieving their desired control objectives, and our management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

***Management's Remediation of the Material Weakness***

As a result of this material weakness, we designed, implemented, and operated new controls as part of our remediation measures which included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a control to review final expense aged receivables on a timely basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a control to evaluate the completeness and accuracy of the final expense third party carrier information received, including verification of lapse status; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a control to evaluate the completeness and accuracy of the information used in the review of provision rates used to develop estimates of first year commission revenue provision.

As a result of the remediation activities and controls described above, we have remediated the previously disclosed material weakness as of December 31, 2022. However, completion of remediation does not provide assurance that our remediated controls will continue to operate properly or that our financial statements will be free from error.

***Changes in Internal Control over Financial Reporting***

Except for the remediation of the material weakness and changes described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**PART II**

**OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

A discussion of legal proceedings to which the Company is a party is included in Part I, Item 1 hereof under "Note 8, Commitments and Contingencies – Legal Contingencies and Obligations," which is incorporated herein by reference.

**ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors set forth in our Annual Report and subsequent periodic filings. Before investing in our securities, we recommend that investors carefully consider the risks described in our Annual Report, including those under the heading "Risk Factors." Realization of any of these risks and any additional risks and uncertainties not currently known to us or that we have deemed to be immaterial could have a material adverse effect on our business, financial condition, or results of operations.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

Not applicable.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

Not applicable.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

Not applicable.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**ITEM 6. EXHIBITS**

The following documents listed below are incorporated by reference or are filed or furnished, as applicable, with this Quarterly Report on Form 10-Q.

---

| | |
|:---|:---|
| Exhibit Number | Exhibit Description |
| <u>[31.1](exhibit311to10-q2q2023.htm)</u> | Certification of Chief Executive Officer of SelectQuote, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| <u>[31.2](exhibit312to10-q2q2023.htm)</u> | Certification of Chief Financial Officer of SelectQuote, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| <u>[32.1](exhibit321to10-q2q2023.htm)</u>† | Certification of Chief Executive Officer of SelectQuote, Inc. Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| <u>[32.2](exhibit322to10-q2q2023.htm)</u>†  | Certification of Chief Financial Officer of SelectQuote, Inc. Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

† &nbsp;&nbsp;&nbsp;&nbsp;The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q, are not deemed filed with the SEC and are not to be incorporated by reference into any filing of SelectQuote, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

------

<u>[**Table of Contents**](#icb71b0e22bc6448b866d18eb9d59d019_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| | **SELECTQUOTE, INC.** |
| February 7, 2023 | By: /s/ Tim Danker |
|  | Name: Tim Danker |
|  | Title: Chief Executive Officer |
|  | By: /s/ Ryan Clement |
|  | Name: Ryan Clement |
|  | Title: Interim Chief Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Tim Danker, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SelectQuote, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

Date: February 7, 2023

---

| |
|:---|
| /s/ Tim Danker |
| Name: Tim Danker |
| Title: Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**Certification of Chief Financial Officer Pursuant to Section**

**302 of the Sarbanes-Oxley Act of 2002**

I, Ryan Clement, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SelectQuote, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

------

Date: February 7, 2023

---

| |
|:---|
| /s/ Ryan Clement |
| Name: Ryan Clement |
| Title: Interim Chief Financial Officer <br>(Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. § 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

&nbsp;&nbsp;&nbsp;&nbsp;I, Tim Danker, the chief executive officer of SelectQuote, Inc. (the "Company"), certify for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

a.&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report of the Company on Form 10-Q for the period ended December 31, 2022 (the "Report"), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;

b.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 7, 2023

---

| |
|:---|
| /s/ Tim Danker |
| Name: Tim Danker<br>Title: Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. § 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

&nbsp;&nbsp;&nbsp;&nbsp;I, Ryan Clement, the interim chief financial officer of SelectQuote, Inc. (the "Company"), certify for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

a.&nbsp;&nbsp;&nbsp;&nbsp;the Quarterly Report of the Company on Form 10-Q for the period ended December 31, 2022 (the "Report"), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;

b.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 7, 2023

---

| |
|:---|
| /s/ Ryan Clement |
| Name: Ryan Clement<br>Title: Interim Chief Financial Officer <br>(Principal Financial Officer) |

---

<br>